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ABSTRACT 
 
RUNX1, a transcription factor required for hematopoiesis and lymphocyte 
differentiation, is one of the most commonly targeted genes in hematopoietic 
malignancies. Mutations in the RUNX1 gene are associated with a poor prognosis 
in a subset of T cell acute lymphoblastic leukemia (T-ALL) and RUNX1 has been 
proposed as a tumor suppressor in TLX1/3-transformed human T-ALL. Recent 
ChIP-seq studies in human T-ALL cell lines demonstrated that a large portion of 
TAL1- and NOTCH1- bound regions contain RUNX binding sites in promoter or 
enhancer regions, suggesting oncogenic roles for RUNX1 in T-ALL. To interrogate 
RUNX1 functions in leukemogenesis, we depleted RUNX1 in a T-ALL mouse 
model and in human T-ALL cell lines. We found that RUNX1 is required for the 
maintenance of mouse T-ALL growth in vivo and the survival of human T-ALL cell 
lines in vitro. In addition, inhibition of the RUNX1 activity with a small molecule 
inhibitor impairs the growth of human T-ALL cell lines and primary patient samples. 
RUNX1 depletion reduces the expression of a subset of TAL1- and NOTCH1-
regulated genes including the MYB and MYC oncogenes, respectively. We 
demonstrate that RUNX1 regulates transcription factor binding and acetylation of 
H3K27 at the Myb and Myc enhancer loci. These studies provide genetic and 
pharmacological evidences that RUNX1 supports T-ALL cell survival and suggest 
RUNX1 inhibitor as a therapeutic strategy in T-ALL treatment. 
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Chapter I 
Introduction  
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T cell acute lymphoblastic leukemia (T-ALL) is a disease of immature 
transformed lymphoid cells expressing T-cell linage markers. T-ALL accounts for 
about 20% of ALL cases and an estimated 6590 new cases of ALL were 
diagnosed in 2016 (American Cancer Society). Although intensive chemotherapy 
regimens have significantly improved outcomes of the patients, they often suffer 
from side effects of the therapies, such as learning disorder, cardiovascular 
impairment, and nervous system toxicity. Those patients who relapse have a 
poor prognosis, with less than 25% rate of survival (1,2). Therefore, 
understanding the molecular basis for T-ALL initiation and maintenance is 
fundamental for the development of improved treatment strategies. Since T-ALL 
is derived from abnormal T-cells, it is important to understand the normal process 
and molecular basis of hematopoiesis and T-cell development in comparison with 
T-ALL pathogenesis. 
Hematopoiesis and T-cell development 
 Hematopoiesis is a hierarchical process that generates all of the cellular 
components of blood from more immature cells. Advances in research 
techniques have made it possible to stratify hematopoietic cell lineages and to 
study the roles of each cell type. By using flow cytometry, blood cell lineages 
have been grouped according to the expression of cell surface markers (3). The 
function of each lineage has been determined by reconstitution of mice with 
sorted cells and by in vitro colony forming assays. Recently, combined 
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transcriptome, epigenome, and proteome analyses at the single cell level have 
been employed in order to refine the understanding of hematopoietic progression 
(4). Murine hematopoiesis is the best understood system at this time and 
evidence suggests that human hematopoiesis is similar to that of mice.    
All blood lineages arise from hematopoietic stem cells (HSCs) that reside 
in bone marrow medulla and have the ability to self-renew (5–7). HSCs consist of 
two populations that differ in their degree of self-renewal capacity and life span: 
long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs) (6,8–10). LT-HSCs 
can divide without losing their self-renewal ability and can differentiate into any 
blood cell (6). LT-HSCs have been defined by a cell surface profile of Lin-Sca1+c-
Kit+CD34-Flt3- (6,11,12) or alternatively by CD150+CD48-CD224- SLAM markers 
(13,14). ST-HSCs have limited self-renewal capacity but are still able to 
differentiate to all blood lineages. The immunophenotype of ST-HSCs is similar 
with LT-HSCs except increased expression of CD34 (CD34hi). ST-HSCs 
differentiate into multipotent progenitor cells (MPPs), which have multilineage 
potential but are not able to self-renew. This population is distinguished from 
HSCs by expression of Flt3 (Flt3hi) (11).  
According to the classic model of hematopoiesis hierarchy, MPPs give rise 
to two populations that are restricted to myeloid progenitors (common myeloid 
progenitors [CMPs],	Lin-IL-7Ra-Sca-1-c-Kit+FcgRloCD34+) or lymphoid progenitors 
(common lymphoid progenitors [CLPs], Lin-IL-7Ra+Thy-1-Sca-1loc-Kitlo) (15,16). 
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CMPs then differentiate into granulocyte-macrophage progenitors (GMPs, Lin-IL-
7Ra-Sca-1-c-Kit+FcgRhiCD34+) and megakaryocyte-erythrocyte progenitors 
(MEPs, Lin-IL-7Ra-Sca-1-c-Kit+FcgRloCD34-) (15). GMPs finally give rise to 
monocytes, granulocytes, and dendritic cells while MEPs differentiate into 
erythrocytes and megakaryocytes. CLPs give rise to all lymphoid lineages 
including T-, B-, and natural killer (NK) cells (16,17). 
Recently, a population of cells derived from ST-HSCs that sustains 
potential for lymphoid lineages as well as GMPs but not for erythrocyte and 
megakaryocyte lineages has been identifed (18,19). This population, named as 
lymphoid-primed multipotent progenitors (LMPPs) is the major progenitor cells 
migrating to the thymus and differentiate into T-cell lineages while losing potential 
for other lineages (20). The first progenitors seeded in the thymus are designated 
as early thymic progenitor cells (ETP; Lin-Sca1+c-Kit+CD24lo/+CD25-
CD44+IL-7Ralo/-) that are found in double negative 1 (DN1; CD4-CD8-CD25-
CD44+) fraction (21,22). Intrathymic signals, such as the NOTCH signal, instruct 
the progenitor cells to commit to T-cell lineages (20,23). Thymocytes physically 
travel through the thymus as they differentiate where they encounter various 
microenvironments and receive different signals from thymic stroma or epithelium 
cells of the thymus (24,25). DN1 cells give rise to DN2 cells that begin to express 
CD25 (CD25+CD44+). It has been demonstrated that DN2 cells can then be 
divided into two subgroups DN2a and DN2b, based on c-Kit expression; DN2b 
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cells that lose c-Kit expression are no longer able to differentiate into dendritic 
cells (26).  
As DN2b cells transition to the DN3 stage (CD25+CD44-), where the 
thymocytes fully commit to the T-cell lineage and stop proliferating while 
simultaneously initiating rearrangement of T-cell receptor (TCR) b, d, and g gene 
loci, catalyzed by recombinase activating gene 1 (RAG1) and RAG2 (27). 
Rearranged TCRb chains pair with the invariant pre-TCRa and CD3 molecules to 
form pre-TCR complexes on the cell surface (28). Only thymocytes that 
successfully rearrange the TCRb gene and produce the functional pre-TCR 
undergo b-selection and receive signals to proliferate and differentiate into DN4 
cells, to initiate the TCRa gene rearrangement, and to express CD4 and CD8 
molecules (29). If DN3 cells successfully rearrange the TCRd or TCRg gene 
instead of b gene, these cells are selected as gd T-cells (30). Thymocytes will 
undergo apoptosis if they fail to rearrange one of these loci. According to CD27 
expression, cell size, and the completion of b-selection, the DN3 population can  
also be subtyped into DN3a and DN3b (before and after the b-selection, 
respectively) (29,31). 
Thymocytes that survive b-selection give rise to immature single positive 
CD8 cells (ISP CD8+), and subsequently to CD4+CD8+ double positive (DP) cells 
that acquire cell surface TCRab complexes. Then they undergo both positive and 
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negative selection to become either mature CD4+ or CD8+ single positive cells 
and leave thymus to enter the circulation (32).   
RUNX1 regulates hematopoiesis 
The RUNX proteins, Runt-related transcription factors, are DNA-binding a 
subunits of the heterodimeric transcriptional complex core binding factor (CBF) 
which regulates various developmental processes including cell proliferation, 
differentiation, apoptosis, and lineage specification (33). In mammals, there are 
three RUNX gene family members of: RUNX1, RUNX2, and RUNX3. The RUNX 
genes share a highly-conserved DNA binding RUNT-homology domain (RHD), 
transactivation domain (TAD), and a C-terminal VWRPY motif, which is required 
for the interaction with the co-repressor Groucho (also known as TLE1 
(transducing-like enhancer split) in mammals) (Figure 1.2) (34). All three RUNX 
genes are expressed from two alternative promoters (distal P1 and proximal P2) 
encoding isoforms with distinct N-terminal sequences (33). The formation of 
heterodimers with CBF subunit b (CBFb) increases the binding affinity of RUNX 
proteins to DNA binding motif 5’-PuACCPuCA-3’ and also increases the stability 
of the complexes (35,36). RUNX proteins bind with diverse types of proteins 
including co-activators and co-repressors, thus functioning as both activators and 
repressors of transcription (37–39). They have also been reported to interact with 
several chromatin modifiers, such as polycomb repressive complex1 (PRC1) (40), 
histone deacetylases (HDACs) (41), H3K4 methyltransferase mixed lineage 
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leukemia (MLL) (42), and SWI/SNF chromatin remodeling complex (43). The 
activity and stability of the RUNX proteins are modulated at the post-translational 
level by phosphorylation and acetylation (44–47).  
The different RUNX family proteins have divergent roles in the 
development process, which was demonstrated using mouse knock out models. 
The RUNX1-null mouse is embryonic lethal at E11.5-12.5 due to central nervous 
system hemorrhage and fetal liver anemia (48,49). The RUNX2-deficient mouse 
presents with major defects in osteoblast development resulting in postnatal 
lethality (50,51). Abnormal thymopoiesis, neurogenesis, and gastric epithelial 
hyperplasia were reported in RUNX3-deficient mice (52–55). These different 
diverse phenotypes are due to the distinct tissue specific expression patterns of 
each gene. Hematopoiesis can be rescued by the knock-in of chimeric genes 
expressing the Runx1 N-terminus with the C-terminus of Runx2 or Runx3 in 
Runx1 deficient mice; this provides evidence of partial functional redundancy 
between RUNX proteins (34).  
 While RUNX1 is required for definitive embryonic hematopoiesis, it is 
dispensable for  adult hematopoiesis, though significant defects in the lymphoid 
and megakaryocyte lineages were observed (56,57). Conditional deletion of 
Runx1 using Mx1-Cre in adult mice demonstrated fully maintained, even 
expanded hematopoietic stem cells (HSC, Lin-Sca-1+c-Kit+ population) in BM 
(56–58). BM cells from the Runx1 targeted mice reconstituted all hematopoietic 
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lineages when transplanted into irradiated recipient mice (56,57). However, the 
effects of Runx1 deficiency on the long-term repopulation capability are still 
controversial. Ichikawa et al. (56) demonstrated increased frequency of LT-HSCs 
in Runx1 deleted bone marrow cells while Growney et al. (57) and Cai et al. (58) 
showed decreased or unchanged number of LT-HSCs upon Runx1 deletion, 
depending on which cells were used to assess the repopulation. Whether these 
discrepancies can be explained by differences in experimental methods or 
deletion strategies, remains to be elucidated.  
The numbers of red blood cells and neutrophils in the peripheral blood of 
Runx1 deleted adult mice were normal, suggesting that the development of 
erythrocytes and granulocytes does not require RUNX1 activity (56,57). In 
contrast, remarkably reduced platelet counts were observed in the peripheral 
blood of Runx1-deficient mice, due to defective megakaryocyte maturation 
(56,57). This appears to be correlated with the expression pattern of Runx1, 
which is maintained during megakaryocyte development but is significantly 
decreased in the erythrocytes lineage (59,60). Runx1 targeted mice also 
presented with a mild expansion of the myeloid lineage in the BM and spleen, 
suggesting a myeloproliferative phenotype in these mice (56,57,61).  
RUNX1 directs T-cell maturation 
Conditional Runx1 deletion in adult mice display significantly reduced T- 
and B-lymphocytes in peripheral blood and reduced cellularity of the thymus, 
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which indicates a critical role of RUNX1 in lymphocyte development (56,57,62). 
Runx1 is highly expressed in double negative thymocytes and downregulated 
when cells undergo thymic maturation (63). Conditional targeting of Runx1 in 
bone marrow using Mx1-cre and in thymocytes using Lck-cre resulted in 
differentiation blocks at DN2 and DN3 stages, respectively, and thereby 
prevented the emergence of DP cells (56,64). Runx1-deficient DN4 cells are less 
proliferative, suggesting defective b-selection, which might be due to decreased 
TCRb expression (64). This is supported by RUNX1 binding to the Tcrb enhancer 
(Eb), which promotes the transcription of the complete Tcrb gene (65,66). In 
human thymocytes, RUNX1 regulates TCRd rearrangement by directing RAG1 
binding to recombination signal sequences through physical interaction (67). In 
addition, positive selection and maturation of CD4SP were impaired in Cd4-cre 
Runx1f/f mice (62,64), indicating that RUNX1 is an essential transcription factor 
for thymocyte differentiation.  
RUNX1 also directly represses CD4 expression by binding to the CD4 
silencer, which restricts CD4 expression to appropriate thymocyte populations 
(62,68,69). Mutations in RUNX binding sites in the CD4 silencer region induced 
de-repression of CD4 expression in DN cells and CD8SP cells (62). While 
RUNX1 is required for CD4 repression in DN cells, it is dispensable for 
maintenance of CD4 silencing in mature CD8+ cells (62).  
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RUNX3 regulates the development of CD8+ cells  
Runx3 expression is high in CD8SP thymocytes and cytotoxic T-cells and 
is critical for the specification of CD8SP cells (62–64). Cd4-cre mediated Runx3 
deletion resulted in a reduction of CD8SP thymocytes and cytotoxic T-cells in the 
periphery (64). RUNX3 binds to the Cd8 enhancer regions to activate Cd8 
expression while silencing CD4 expression through binding to the silencer in 
CD8+ cells (62,63). Accordingly, the absence of RUNX3 in CD8 T-cells 
de-repressed CD4 expression and slightly reduced CD8 expression (62,64).     
In addition to silencing CD4 expression directly, RUNX3 represses T-
helper inducing POZ-Kruppel factor (Thpok), a determinant factor of the CD4 
lineage (70). RUNX3 also directly modulates T-cell factor-1 (TCF-1) and 
lymphoid enhancer-binding factor-1 (LEF-1), the upstream regulators of Thpok to 
ensure the specification of CD8+ cells from DP thymocytes (71).  
TAL1/SCL controls hematopoietic lineage specification and development  
 TAL1/SCL (T-cell acute lymphoblastic leukemia 1/stem cell leukemia) was 
first cloned from a T-ALL patient derived cell line as a gene translocated in the 
TCRd locus where it was constitutively expressed (72) and was later found to be 
a crucial gene for hematopoiesis. Disruption of the Tal1 gene in mice resulted in 
growth retardation and embryonic lethality around E8.5 to E10.5 due to the 
absence of yolk sac primitive erythropoiesis (73,74). The absence of all 
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hematopoietic cells from Tal1-null ES cells in adult chimera mice supports the 
theory that TAL1 is required for the specification of hematopoietic lineages 
(75,76). In contrast, conditional deletion of Tal1 in adult mice using Mx1-cre 
displayed only moderate anemia and thrombocytopenia, indicating that 
continuous Tal1 expression is not necessary for the maintenance of HSCs (77). 
In addition, Tal1-deleted HSCs were capable of self-renewing and competing 
with wild type BM cells to reconstitute hematopoiesis in lethally irradiated 
recipients (77,78).  
TAL1 is a class II basic helix-loop-helix (bHLH) family transcription factor 
and binds to the E-box DNA binding motif (CANNTG) as a obligate heterodimer 
with class I bHLH transcription factor E-proteins including E12/E47, HEB, and 
E2-2 (79). TAL1 can either activate or repress target gene expression through 
integration with cofactors such as P300/CBP histone acetyltransferase and pCAF 
(P300/CBP-associated factor) for activation, or mSIN3A for repression (80–82). 
TAL1 also forms regulatory complexes with non-DNA binding proteins such as 
LIM-only domain proteins LMO1/2 and LIM domain-binding protein 1 (LDB1), 
which bridge the TAL1:E-protein heterodimer with other transcription factors, 
including GATA proteins and SP1, to influence its downstream targets (83,84). 
DNA binding activity of TAL1 is not always required for its functions (85–87). In 
normal hematopoiesis, mice carrying mutant Tal1 that cannot bind to DNA 
developed primitive hematopoietic cells, in contrast to the complete absence of 
hematopoiesis in Tal1-null mice (76,85).  
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TAL1/SCL is required for erythrocyte development and is silenced in 
lymphoid lineages   
Tal1 is expressed in hematopoietic stem cells, multipotent progenitor cells, 
erythrocyte and megakaryocyte lineages, but is silenced during lymphocyte 
development (88–90). In vitro colony forming assays with Tal1-depleted BM cells 
revealed that TAL1 is required for erythroid and megakaryocytic cell 
differentiation, but not for lymphoid and myeloid development (77). Forced TAL1 
expression induced differentiation of hematopoietic progenitor cells toward the 
erythroid lineage (91). ChIP-seq studies combined with gene expression analysis 
in immature erythroid progenitor cells revealed that TAL1 regulates the 
expression of genes involved in erythrocyte development, including b-globin 
(HBB), Krueppel-like factor 1 (KLF1), and glycophorin A (GPA), suggesting a 
pivotal role of TAL1 in erythrocyte differentiation (92–94). In addition, direct DNA 
binding of TAL1 is required for the terminal differentiation of erythrocytes (85,92). 
Tal1 expression in thymocytes is restricted to the DN2 stage; ectopic expression 
of TAL1 with LMO1 in thymocytes resulted in the differentiation arrest at the DN 
stage and subsequently leukemogenesis, as described below (89,95).  
NOTCH1 signaling is essential for T-cell development 
NOTCH1 is a class I transmembrane protein receptor that functions as a 
ligand-activating transcription factor, transducing extracellular signals directly to 
the nucleus. NOTCH1 anchors in the cell membrane as a heterodimer composed 
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of an N-terminal extracellular subunit, a C-terminal transmembrane subunit, and 
C-terminal intracellular subunit, which are non-covalently linked through the 
heterodimerization (HD) domain in each subunit (96). These subunits are 
encoded by a single gene and processed into two polypeptides during maturation. 
NOTCH1 interacts with its ligands expressed on adjacent thymic stromal cells, 
such as Delta-like ligand 1 (DLL1), DLL3, DLL4, Jagged1, and Jagged2, through 
36 epidermal growth factor (EGF)-like repeats in the extracellular subunit. Ligand 
binding initiates signaling, first by inducing a conformational change in a negative 
regulatory region (NRR), which allows the cleavage of the HD domain by the 
ADAM10 and ADMA17 metalloproteases at the cell surface (97–100). The 
second cleavage by the g-secretase complex in the transmembrane region 
releases the intracellular domain of NOTCH1 (ICN1) from the membrane and 
leads to its translocation into the nucleus (97,98). In the nucleus, ICN1 
associates with a transcriptional factor RBPJ/CSL, which is bound to DNA with 
corepressors in the absence of NOTCH1, and recruits coactivator proteins such 
as mastermind 1 (MAML1) and p300/CBP to activate its target genes (96). The 
activated signaling is terminated through the C-terminal PEST (proline [P], 
glutamic acid [E], serine [S], and threonine [T] rich) domain of NOTCH1. 
Polyubiquitination of the PEST domain by FBXW7/SCF (F-box and WD repeat 
domain containing 7/SKP1-Cullin-1-F-box protein) ubiquitin ligase complex 
results in proteasomal degradation of ICN1 (96).  
	 
14 
T-cell development within the thymus is directed by signals from 
thymocytes themselves and from interactions between thymocytes and thymus 
stroma (101). NOTCH-mediated signaling is one of the pathways pivotal for 
T-cell development (101). There are four family members of NOTCH in mammals, 
which are named NOTCH1-4, and perform variety roles in normal cellular 
processes such as lineage commitment, proliferation, apoptosis, and 
differentiation, as well as in human malignancies (96). In lymphoid cells, all four 
NOTCH proteins are expressed at different levels (102,103). NOTCH1 is 
expressed in thymocytes and has been known to be critical for T-cell 
development (discussed below) (96,102–104). The expression of NOTCH2 is 
high in B-cells and NOTCH2 deficiency in BM cells impairs B-cell maturation but 
not T-cell development (105). NOTCH3 is expressed in the T-cell lineage, in 
similar patterns as NOTCH1 expression, but targeting NOTCH3 showed only 
mild effects on T-cell development (106), suggesting that NOTCH1 plays the 
dominant role in T-cell development. Lastly, NOTCH4 is expressed weakly in 
immature DP cells, but the role of NOTCH4 in T-cell development has not been 
determined (103). 
NOTCH determines the fate of committed T-cells between ab and gd T-cell 
lineages (107–109). The fraction of thymocytes at the DN3a stage that 
successfully rearranges the TCRb gene, assembles the pre-TCR composed of 
TCRb, pre-TCRa and CD3 protein, and commits to the ab T-cell lineage. 
Signaling through the pre-TCR induces ab T-cells to proliferate extensively and 
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to differentiate into DN3b, DN4, and DP cells (109). Deletion of NOTCH1 or 
RBPJ/CSL in immature thymocytes using Lck-Cre results in a differentiation 
block of ab T-cells at DN3 stage due to impaired V-DJb rearrangement, and 
consequently, the significantly reduced number of DP cells (107,108). In addition, 
NOTCH signaling regulates pre-Ta gene expression in association with E47 
(110,111). Interestingly, the number of gd T-cells was increased in RBPJ/CSL-
deficient mice, but not in mice deficient for NOTCH1 (107,108). These data imply 
that other NOTCH receptors may contribute to T-cell fate decisions, and that the 
role of NOTCH1 may be restricted to the generation and maintenance of ab T-
cells. 
In vitro T-cell differentiation studies demonstrated that NOTCH signaling is 
required for the survival and proliferation of immature thymocytes (112–114). 
Expression of DLL1 in OP9 stroma cells has been shown to be sufficient to 
maintain hematopoietic progenitor cells and to induce DP thymocyte 
differentiation in cell culture systems (115). In the absence of the interaction 
between the NOTCH receptor and its ligand, however, DN3 cells rapidly undergo 
apoptosis due to the lack of glucose metabolism associated with PI3K 
(phosphatidylinositol 3-kinase)-AKT (serine-threonine kinase) pathway (114). 
Proliferation of DN3 thymocytes upon CD3 induction was also impaired by 
withdrawal of NOTCH1 signaling (113).  
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T-cell acute lymphoblastic leukemia and current therapies for patients with 
T-ALL 
 T-ALL is a disease characterized by the uncontrolled proliferation of 
immature T lymphocytes. T-ALL accounts for 10-15% of pediatric and 20-25% of 
adult ALL cases and is associated with anemia, thrombocytopenia, neutropenia, 
and high white cell counts with atypical blasts in the blood. Patients with T-ALL 
frequently present with a mediastinal thymic mass and leukemic infiltration of the 
central nervous system at diagnosis (1,116). 
The main therapeutic approach for T-ALL is repeated cycles of 
chemotherapy, regardless of genetic abnormalities. Rigorous therapeutic 
regimens have improved the outcome of the disease with five-year disease-free 
survival rates of over 80% in pediatric T-ALL patients, which is  still inferior to that 
of pediatric B-ALL patients (117). The outcome of adult patients with T-ALL is 
poor, with about a 50% 5-year survival rate (118,119). When disease relapse 
occurs, the prognosis is even worse, less than 25% of patients survive long term 
(120,121). 
Chemotherapy regimens for patients with T-ALL consist of several phases 
including induction, consolidation, and maintenance. Induction therapy is given 
for 4 to 6 weeks and is a combination of glucocorticoids (prednisone or 
dexamethasone), vincristine, and L-asparaginase. The high-risk group of patients 
will also receive an anthracycline class drug such as doxorubicin, epirubicin, and 
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valrubicin. More than 90% of patients attain remission, though additional 
treatments are required for preventing relapse. To consolidate the remission and 
prevent development of CNS leukemia, intensive chemotherapy composed of 
methotrexate and 6-mercaptopurine or 6-thioguanine will be used for 1 to 2 
months. Vincristine, L-asparaginase, doxorubicin, and etoposide may be added. 
If children stay in remission after the consolidation phase, maintenance therapy 
may begin. Daily 6-mercaptopurine and weekly methotrexate, often with 
vincristine and glococorticoid will be given for 18 to 30 months as maintenance 
therapy (1)(American cancer society). 
Approximately 1% to 2% of children die from toxic effects of therapy 
during remission, mostly due to infection (122,123). Intensive chemotherapy 
results in several side effects as well, the most prominent being osteonecrosis, 
which occurs in 5-10 % of pediatric ALL patients (124,125). Additional side 
effects include metabolism syndrome, obesity, cardiovascular impairment, and 
CNS toxicity, and peripheral nervous system toxicity (1). In addition, children who 
survive ALL have been shown to suffer from learning disorders and secondary 
malignancies such as brain cancer and non-Hodgkin lymphoma (126,127). 
Therefore, targeted therapies have been the focus of pharmaceutical 
development in order to reduce adverse side effects while improving remission 
rates. 
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Genetic alterations in oncogenes and tumor suppressors drive T-ALL 
leukemogenesis 
T-cell transformation results from the accumulation of multiple genetic 
abnormalities. Mutations that disrupt the functions of oncogenes, tumor 
suppressors, and genes involved in cell cycle, proliferation, survival, and 
differentiation of normal thymocyte development have been identified in T-ALL 
(128). T-ALL is subgrouped into early T cell precursor T-ALL (ETP-ALL), and 
early or late cortical T-ALL based on the immunophenotype reflecting the stage 
of thymic maturation arrest (129). Each subgroup exhibits a distinct gene 
expression profile defined by altered expression of transcription factors (129). 
The immunophenotype and gene expression profile of ETP-ALL resemble that of 
ETP cells (130). In addition, ETP-ALL harbors mutations commonly found in 
myeloid leukemias, including FLT3, ETV6, and NRAS (131). T-ALL cells with the 
early cortical thymocyte immunophenotype (CD1a+CD4+CD8+) are associated 
with activation of TLX1/3 and NKX2-1/2 transcription factors (129). Late cortical 
T-ALL cells express CD3, CD4, and CD8, an immunophenotype corresponding 
to the late stage of cortical thymocyte maturation and typically misexpress TAL1 
(129). Among the subgroups, ETP-ALL is a high-risk subtype while early cortical 
T-ALL subtype shows a favorable prognosis (132,133,130). 
Despite the infrequency of cytogenetic abnormalities, about 35% of T-ALL 
exhibits chromosomal translocations involving TCR genes and T-cell specific 
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transcription factors (134,135). The rearrangements place strong regulatory 
elements of TCRb or TCRa/d genes near transcription factors including TAL1 
(72,136,137), TAL2 (138), LYL1 (139), BHLHB1 (140), TLX1/HOX11 (141,142), 
TLX3/HOX11L2 (143), LMO1 (144), LMO2 (145), MYB (146), and MYC 
(147,148), which result in aberrant activation of the affected transcription factors 
leading to transformation of T-cells.    
Chromosomal deletions leading to loss of tumor suppressors also occur in 
T-ALL. Over 70% of T-ALL exhibits deletion of cyclin-dependent kinase inhibitor 
2A (CDKN2A) locus at chromosome 9p21, which encodes p16INK4A and p14ARF, 
resulting in uncontrolled cell proliferation (149,150). Broad deletions of 
chromosome 6q14-23 were observed in 19.3% of pediatric T-ALL cases, 
although the related tumor suppressors have not yet been identified (150).  
Other activating and loss of function mutations in NOTCH1, NRAS, FLT3, 
NF1, and PTEN, were identified in T-ALL (131,151–154). Among them, activation 
of the NOTCH1 pathway is one of the most frequent genetic mutations in T-ALL 
and will be discussed below. Recent sequencing studies have demonstrated that 
epigenetic regulators such as PHF6, EED, EZH2, SUZ12, and KDM6A are also 
deleted or mutated in T-ALL (131,155–158). Genome-wide studies combined 
with integrated analyses have identified genetic alterations and the associations 
between mutations defining the genomic landscapes of T-ALL (150). Functional 
studies have provided additional rationale for new therapeutic approaches. 
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Activating mutations in NOTCH1 is prevalent in T-ALL 
NOTCH1 mutations resulting in abnormal activation of downstream 
signaling pathways have been observed in more than 60% of T-ALL patient 
samples regardless of the subtype of T-ALL, though the highest association is 
found in the early cortical TLX1/3 positive T-ALL subtype (151,159). Aberrant 
activation of NOTCH1 in T-ALL was first identified in rare cases carrying a 
chromosomal translocation t(7;9)(q34;q34.3), generating a truncated 
constitutively active NOTCH1 allele (160). A subsequent experiment that 
reconstituted mice with bone marrow progenitor cells expressing activated forms 
of NOTCH1 resulted in the development of T-ALL, providing direct evidence that 
NOTCH1 is oncogenic in T-ALL (161).  
Most NOTCH1 activating mutations localize to the HD or PEST domains 
(151,159). Mutations in the HD domain, which account for about 40% of T-ALL 
cases, result in ligand-independent NOTCH1 activation or ligand hypersensitivity 
(162). Nonsense or truncating mutations in the PEST domain have been 
observed in approximately 15% of T-ALL patients. The result of these mutations 
is the loss of the recognition sequences by FBWX7/SCF complex and 
consequentially impaired degradation of activated ICN1 (151,163–165). In rare 
cases, NOTCH1 is activated in a ligand-independent manner by in-frame 
insertions at the extracellular juxtamembrane region (juxtamembrane expansion, 
JME), which reposition the HD domain away from the membrane (166). In 
	 
21 
addition to the mutations found in NOTCH1 genes, about 15% of T-ALLs carry 
FBXW7 mutations (167,168). These mutations typically reside in key residues 
responsible for the recognition of phosphorylated NOTCH1 PEST domain thus 
failing to degrade the activated ICN1 (167,168). Since FBXW7 targets other 
oncoproteins such as MYC, JUN, Cyclin E, and mTOR (169–171) for degradation, 
FBWX7 mutations might augment tumorigenesis.  Interestingly, majority of T-ALL 
patients harbor either double mutations in the HD and PEST domain of NOTCH1 
(~20%) or mutations in NOTCH1 HD domain and FBXW7 mutation together 
(~60%). The combined mutations synergistically activate NOTCH1 signaling due 
to ligand-independent activation combined with ICN1 degradation (151,168). 
Activating NOTCH1 mutations were also found in T-ALL mouse models. 
First, in T-ALL developed using MMTVD(mouse mammalian tumor virus)/Myc 
transgenic mice, more than 50% of provirus insertions took place in the Notch1 
gene, resulting in constitutive NOTCH1 activation (172) and 74% of leukemic 
cells from Lck-Tal1 driven T-ALL mouse model harbored spontaneous mutations 
in Notch1 (173). Deletions of 5’ region of the Notch1 gene were the majority of 
mutations identified in mouse T-ALL cells (174). These deletions resulted in 
ligand-independent activation of NOTCH11 signaling, which mimicked HD 
domain mutations in human T-ALL cells (174). In addition, NOTCH1 mutations 
were observed in pre-leukemic cells from Lck-Tal1/Lmo2 or pSil-TSCL/Lck-LMO1 
bitransgenic mice (175,176), indicating that NOTCH1 activation is important at 
the early stage of transformation.  
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The activation level of each NOTCH1 mutation is not equivalent, thus 
results of the overexpression of individual NOTCH1 mutant alleles or 
combinations of them in mouse hematopoietic progenitor cells yield differing 
results (177). Typically mutations in the PEST domain are considered to be weak 
alleles and require other oncogenes such as K-ras to initiate T-ALL in mouse 
models (177). However, most of the Notch1 mutations found in Tal1-induced 
murine leukemic cells were mapped to the PEST domain (173). Collectively, 
while strong NOTCH1-activating mutations, including rare truncated NOTCH1 
alleles resulted from the chromosomal translocation (<1%) and double mutant 
alleles (HD with PEST or HD with FBXW7 mutations), may play a role as driving 
oncogenes, others mutations might contribute to the progression of T-ALL 
pathogenesis. The inhibition of tumor growth upon treatment with g-secretase 
complex inhibitors (GSIs) in T-ALL engrafted mice models (175,178) underscores 
the important roles of NOTCH1 in T-ALL maintenance. 
NOTCH1 directly regulates MYC expression in T-ALL 
Understanding the role of aberrant NOTCH1 activation in T-ALL led to 
extensive efforts to reveal downstream pathways and target genes of NOTCH1. 
ChIP-seq and gene expression analyses revealed that NOTCH1 directly 
regulates the expression of genes involved in cell metabolism and anabolic 
pathways, including ribosome biosynthesis, protein translation, and nucleotide 
and amino acid metabolism (179), supporting the role of NOTCH1 in the control 
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of cell growth. Consistent with this, NOTCH1 inhibition by GSI treatment reduced 
cell size (179). 
 Among the list of NOTCH1 target genes, MYC, the central regulator of cell 
metabolism and required for entry into S-phase, was identified as one of the top 
responsive genes upon NOTCH1 inhibition by GSI treatment or silencing (179). 
Several independent studies confirmed that MYC is a direct target gene of 
NOTCH1 in T-ALL, as well as in breast cancer (180–182). NOTCH1 binding to 
the Myc promoter region was validated using chromatin immunoprecipitation 
(ChIP) (180–182). Moreover, Myc overexpression rescued the apoptosis and G1 
cell cycle arrest induced by NOTCH1 inhibition, while inhibition of MYC impeded 
the  NOTCH1-medited growth (180,181). It has been reported that MYC target 
genes were enriched in NOTCH1-regulated genes (179) and that MYC binds to 
the majority of NOTCH1-bound promoter regions (183), indicating that MYC is an 
essential mediator and collaborator of the NOTCH1 pathway.  
MYC is a basic helix-loop-helix leucine zipper transcription factor, 
controlling the expression of genes mediated in various cellular growth processes 
including DNA replication, cell cycle regulation, cell metabolism, and ribosome 
biogenesis (184–186). The expression pattern of Myc during thymocyte 
development mimics that of Notch1, and is increased at DN3/4 stages while 
silenced in the transition to DP cells (102,187), consistent with the finding of MYC 
as a NOTCH1 target gene. Pre-TCR signaling also contributes to the increase in 
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MYC protein levels at the DN3 stage, leading to proliferation of DN3 cells (188). 
Without Myc expression, the number of thymocytes was remarkably reduced 
while thymocyte differentiation was not impaired (188). 
The overexpression of MYC was first discovered in Burkitt’s lymphoma 
which results from chromosomal translocation t(8;14)(q23;q32) (189), and has 
subsequently been found deregulated in several hem-malignancies, including T-
ALL (190–192). In addition to chromosomal rearrangement, mutations and gene 
amplification can lead to the MYC overexpression (190,191). Diverse oncogenic 
pathways including NOTCH1, MAP kinase, and WNT signaling induce MYC 
activity by upregulation of transcription or increase in the protein stability (179–
181,193,194). It has been shown that overexpression of MYC contributes to 
tumor initiation, malignant cell proliferation, and survival (192).     
Before becoming known as a direct target of NOTCH1, the contribution of 
MYC in T-ALL pathogenesis was implicated from the recurrent observation of 
chromosomal translocation t(8;14)(q24;q11) affecting MYC expression 
(147,148,195). As result of the translocation, MYC gene expression is under 
control of the strong regulatory element of TCRA/TCRD genes (195). The MYC 
protein half-life is controlled by FBXW7-mediated proteasomal degradation (196). 
Thus, loss-of-function mutations on FBXW7 in T-ALL increase the protein 
stability of ICN1 and MYC.  In addition, the increased MYC level in primary T-ALL 
patient samples without the NOTCH1/FBXW7 mutations was observed, 
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indicating NOTCH1 independent mechanisms of MYC deregulation in T-ALL 
(197). Phosphorylation of MYC by GSK3B enhances proteasomal degradation of 
MYC (198). Inhibition of GSK3B by AKT activation resulted from PTEN loss has 
been suggested as one additional mechanism of MYC regulation (197). 
Targeting the NOTCH1-MYC pathway inhibits T-ALL leukemogenesis 
In accordance with the prevalence of NOTCH1 aberrant activation and the 
importance of MYC activity in T-ALL, inhibiting NOTCH1 signaling has been 
shown to effectively interfere with T-ALL development. The effect of NOTCH 
pathway suppression has been tested with treatment of GSI in in vitro and in vivo 
systems. The g-secretase complex cleaves all NOTCH family members and their 
ligands (199,200). It also targets growth hormone receptor and cell adherence 
molecules such as E- and N-cadherin (201,202). In T-ALL, enforced expression 
of ICN1 sufficiently overcame the phenotype induced by GSI treatment, 
suggesting that NOTCH1 is the major substrate of g-secretase complex in this 
cell type (180,181). GSI treatment of T-ALL cells resulted in clearance of ICN1 
and downregulated the expression of NOTCH1 target genes (151,179,180). 
NOTCH1 inhibition in human T-ALL cell lines resulted in G1 cell cycle arrest, 
decreased cell growth and proliferation, and reduced cell size (179,180). Our lab 
first demonstrated that murine T-ALL cells undergo apoptosis upon GSI 
treatment (167,178,203). We also showed that administration of GSI to leukemic 
mice extends or prolongs disease latency (175,178). In addition, engraftment of 
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leukemic cells pre-treated with GSI was impaired, confirming that inhibition of 
NOTCH1 signaling suppresses initiation as well as maintenance of T-ALL 
(175,204).    
Targeting MYC in T-ALL is attractive since we showed that Myc inhibition 
or silencing eliminating leukemia-initiating cells (LICs), which are responsible for 
the disease initiation in recipient mice, self-renew, and relapse of the disease in 
patients. In a NOTCH1-activated background, mutation of FBXW7 enhanced 
MYC protein stability and as a result, increased the number of LICs (196). On the 
other hand, depletion or inhibition of MYC by genetic ablation, shRNA expression, 
or pharmacologic treatment interfered with T-ALL development and decreased 
the number of LICs (196,205). MYC expression is highly sensitive to JQ1, an 
inhibitor of BRD4 (BET bromodomain-containing protein 4), which is a chromatin 
reader protein binding to acetylated histone, especially in hematopoietic cells 
(206). The effect of MYC inhibition on the induction of leukemic cell death was 
superior to NOTCH1 inhibition by GSI treatment in both mouse and human 
primary T-ALL cells (205). This was in agreement with the idea that MYC activity 
is controlled by other pathways other than NOTCH1 (193,197), and suggested 
that targeting MYC may be more successful for the inhibition of T-ALL 
pathogenesis.  
 The importance of targeting MYC to induce suppression of T-ALL also 
came from efforts to find a mechanism for how T-ALL cells acquire resistance to 
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GSI (207,208). It was reported that GSI-sensitive human T-ALL cell lines could 
become GSI resistant following prolonged culture with GSI  (persister cells) (207). 
Persister cells expressed undetectable levels of ICN1 but moderate levels of 
MYC (207). In addition, BRD4 was found to be required for the maintenance of 
persister cells specifically, and binding loci of BRD4 and H3K27ac in persister 
cells were distinct from those in treatment-naïve cells, indicating that the 
epigenetic changes were involved in the acquisition of GSI resistance (207). 
Treatment with JQ1 or rapamycin, an inhibitor of mTOR, reduced MYC 
expression to a very low level and inhibited the proliferation of persister cells 
(207). Our lab demonstrated that treating NOD-scid IL2Rg-/- (NSG) mice 
engrafted with relapsed T-ALL patient cells with NOTCH1 inhibitor DBZ and JQ1 
together also prolonged the survival of leukemic mice (207). These results stress 
the importance of MYC expression on T-ALL maintenance, and therefore the 
effectiveness of MYC targeting for T-ALL inhibition. 
NOTCH1 downstream pathways can be therapeutic targets for T-ALL 
Other than MYC, NOTCH1 has been found to control the PI3K-AKT-
mTOR signaling pathway in T-ALL; this pathway is one of critical regulators of 
cell growth and metabolism. The upregulation of the PI3K-AKT-mTOR pathway 
was detected in over 85% of pediatric T-ALL patients resulting from various 
mechanisms, including mutations in	PI3K, AKT, and loss of function mutations or 
inactivation of PTEN (154,209,210). In particular, loss of PTEN was reported in 
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17% of patient cases and resulted in GSI resistance (154). NOTCH1 activation 
and PTEN loss appeared to cooperate in T-ALL pathogenesis (178,211). 
NOTCH1 inhibition in T-ALL seems to be able to suppress this pathway at 
several levels. HES1, a direct target of NOTCH1, is a well-known transcriptional 
repressor and was shown to downregulate PTEN gene expression by binding at 
the promoter sequences (154). PTEN negatively regulates the PI3K-AKT-mTOR 
pathway by removing the 3-phosphate from phosphoinositide 3,4,5 triphosphate 
(PlP3) and destabilizing PI3K-mediated membrane recruitment of AKT required 
for activation. PTEN is also post-translationally inactivated by phosphorylation by 
casein kinase 2 (CK2) (209). Consistent with this, combined treatment with CK2 
inhibitors and GSI was more effective for T-ALL inhibition compared with each of 
the single reagent treatments (212).    
Additional NOTCH1 target genes, including Interleukin receptor 7 alpha 
chain (IL7Ra), PTCRA , and insulin-like growth factor 1 receptor (IGF1R), are 
important factors for T-ALL proliferation and are also upstream PI3K regulators 
(111,213,214). The LCK tyrosine kinase expressed in T cells can activate AKT 
downstream of NOTCH1 signaling (215). Targeting each gene with inhibitors 
such as BMS-526924 and NAC against IGF1R and IL7R, respectively, inhibited 
cell proliferation (214,216). In addition, combinational therapies targeting PI3K 
and mTOR with NOTCH1 inhibition have shown efficacy in pre-clinical models 
(178,217,218). A recent report that NOTCH1 regulates PP2A dephosphorylation 
of AKT suggested modulation of PP2A activity as a potential T-ALL therapy (219).   
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 NOTCH1 activation has also been shown to stimulate NF-kB activity (220). 
Mechanistically, NOTCH1 directly regulates the expression of NF-kB factors 
RelB and Nfkb2 and induces their nuclear localization (220). In addition, HES1, a 
direct target of NOTCH1, represses deubiquitinase CYLD expression, which 
results in activation of the IkB kinase (IKK) complex and upregulation of NF-kB 
target genes, including intercellular adhesion molecule 1 (ICAM1) and BCL2 
related protein A1 (BCL-2A1) (220,221). Consistent with these data, targeting 
NF-kB using a small molecule inhibitor significantly induced apoptosis of T-ALL 
cells  which synergized with GSI treatment (220).   
It has been discovered that NOTCH1 signaling promotes G1/S cell cycle 
progression by transcriptionally activating cell cycle regulators such as cyclin D3 
(CCND3), cyclin dependent kinase 4 (CDK4), and CDK6 (222,223). CCND3 was 
required for NOTCH1-induced T-ALL development (224). A negative regulator of 
CCND3, CDKN2A (p16INK4a) is inactivated in T-ALL by mutation, deletion, or 
silencing in approximately 90% of T-ALL cases (149,225,226). In contrast, the 
expression of other negative regulators of CDK, CDKN2D (p19INK4d) and 
CDKN1B (p27Kip1), was upregulated in GSI-treated cells to exit cell cycle (223). 
Consistent with this, blocking CDK4/6 activities by inhibitor treatment, with or 
without NOTCH1 inhibition, effectively interferes with T-ALL progression 
(223,227,228).   
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NOTCH1 as a candidate for targeted T-ALL therapy 
NOTCH1 inhibition is a promising option, due to the prevalence of 
NOTCH1 pathway mutations, and has been extensively studied. The effects of 
NOTCH1 inhibition by GSI treatment in T-ALL cell lines and mouse models were 
encouraging, with rapid regression of leukemic cells observed. However, a 
clinical trial with MK-0752, an oral GSI developed by Merck was not successful 
(229). Patients who participated in the trial showed continued disease 
progression and severe drug-related toxicities, including diarrhea due to inhibition 
of NOTCH signaling in the gut (229). Our lab demonstrated that an intermittent 
dosing regimen reduced gastrointestinal toxicity while suppressed leukemia 
progression in T-ALL mice model (178). This dosing regimen in patients with 
melanoma was well-tolerated but showed minimal activity against the disease in 
a clinical trial, possibly due to insufficient exposure to the drug (230). Therefore, 
alternative strategies may need for successful administration of GSIs. 
Combination treatment of GSIs and other molecularly targeted inhibitors 
has been investigated in order to improve the safety and efficacy of NOTCH1 
inhibition. As discussed earlier, in combination with GSIs, treatment with 
inhibitors of CDK4/6, the PI3K-AKT-mTOR pathway, and NF-kB signaling have 
shown to be effective in T-ALL inhibition(154,178,220,223).  
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A driving oncogenic factor, TAL1 is misexpressed in T-ALL  
Misexpression of TAL1 has been reported in approximately 60% of 
pediatric and 40% of adult T-ALL and is associated with a poor prognosis (231). 
The activation of TAL1 occurs by interchromosomal translocation with TCRa/d 
(t(1;14)(p33;q11)) (72,136) or TCRb (t(1;7)(p32;q35)) (137) genes or by ~90kb of 
interstitial deletion that places undamaged TAL1 coding regions under the 
promoter of SIL (SCL/TAL1 interrupting locus) gene (232,233). Recently, 
heterozygous somatic mutations were identified at a specific site upstream of the 
TAL1 gene (234). These mutations create an enhancer site containing new MYB 
binding motifs that promote aberrant monoallelic TAL1 activation in T-ALL (234).   
The initial studies of the abnormal TAL1 regulations in T-ALL focused on 
TAL1 interference with E-protein functions, which are important for normal T-cell 
development. Under normal conditions, TAL1 expression is downregulated at the 
early stages of lymphoid development whereas the levels of HEB and E2A are 
increased up to the DP stage of T-cell development (89). The aberrant 
expression of TAL1 has been suggested to deplete HEB and E47 tumor 
suppressors by sequestering them from their target loci (89,235). TAL1 then 
recruits corepressor mSIN3A to the target genes, such as CD4 and pre-TCRa, 
resulting in decreased transcription, and consequently, a differentiation block and 
transformation of the thymocytes (235). In line with this, TAL1 overexpression 
accelerated T-ALL pathogenesis in HEB or E2A heterozygote mice (235). 
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Several genomic occupancy studies revealed that TAL1 shares binding loci with 
HEB and/or E47 (236,237). Combined global gene expression analyses identified 
direct target genes of TAL1 that are activated by TAL1, including TRAF3 (TNF 
receptor associated factor 3, required for T cell effector functions), CDK6 (cyclin 
dependent kinase 6, regulates cell cycle and is downregulated during T cells 
differentiation), as well as genes involved in cell differentiation and apoptosis 
(93,236,237). In addition, TAL1 silencing using shRNA induced leukemic cell 
apoptosis, suggesting that TAL1 is required for leukemic cell maintenance 
(93,237).  
Thymic expression of TAL1, in cooperation with other genetic mutations, 
results in T-ALL in mice 
Efforts to verify the oncogenic activity of TAL1 and to establish a mouse 
model for T-ALL have been made. Unfortunately, the first few attempts with Tal1 
overexpression by the CD2 enhancer failed to develop leukemia or lymphoma in 
mice despite the high expression of TAL1 in thymocytes (238,239). Reconstituted 
mice with bone marrow cells transduced with TAL1 expressing retrovirus did not 
develop T-ALL (240). Other trials overexpressing TAL1 under SIL promoter were 
not successful either (241,242). Finally, when Tal1 was mis-expressed in 
developing thymocytes under the promoter of T-cell specific protein kinase LCK, 
28% of mice was able to develop T-ALL after a long latency (243).  Mice that 
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developed T-ALL presented with infiltration of lymphoblastic cells into the thymus, 
liver, spleen, and kidney, which was similar to human T-ALL (243). 
The pathogenesis of TAL1-induced leukemia was significantly enhanced 
by co-overexpression of other oncogenes such as LMO1/2, a TAL1 activity 
modulator Casein Kinase IIa (CKIIa), or by loss of the CDKN2A locus (241,243–
245). In addition, transgenic expression of p16INK4A prolonged the survival of 
TAL1 and LMO1 bitransgenic leukemic mice, and tumors from diseased mice 
had silenced p16INK4A expression (246).  
LMO1/2 is misexpressed in T-ALL and collaborates with TAL1 to cause 
leukemia in mice 
Overexpression of LMO1/2 has been observed in approximately 45% of 
patients with T-ALL and is highly associated with cases of TAL1 misexpression 
(129,145,247). LMO1/2 are also targets of chromosomal rearrangements 
involving TCR genes and LMO2 can be overexpressed by deletion of a cis-
negative regulator of the LMO2 gene in T-ALL (144,145,248). The oncogenic 
function of LMO2 was discovered from studies using retrovirus-based gene 
therapy for X-linked severe combined immunodeficiency syndrome (SCID-X1) 
(249–251) where 25% of patients who participated in the trials developed T-ALL 
due to LMO2 activation by virus insertion upstream of the LMO2 locus (249–251). 
In addition, enforced expression of LMO1 or LMO2 transgenes in thymocytes 
resulted in the development of T-ALL in mice (252–255).  
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In Tal1-transgenic mice, additional ectopic expression of Lmo1 or Lmo2 
significantly enhanced the penetrance and accelerated the onset of T-ALL 
(87,238,241). All mice expressing Tal1 and Lmo2 transgenes under the Lck 
promoter developed T-ALL with a median survival of about 100 days (87). The 
double transgenic mice with Tal1 and Lmo1 or Lmo2 exhibited abnormalities in 
thymocyte development at the pre-leukemic stage, such as differentiation block, 
reduced thymocyte cellularity, increased cell proliferation, and apoptosis (87,244).  
In normal hematopoiesis, TAL1 and LMO2 share expression patterns and 
the phenotype of Lmo2-null mice is comparable to that of Tal1-null mice (76,256). 
In erythroid cells, LMO1/2 cannot bind to DNA directly but instead forms a 
regulatory complex with the TAL1:E-protein heterodimer and LDB1 through the 
LIM domain, to regulate expression of genes important for erythropoiesis 
(92,238). It is suggested that LMO1/2 may be a critical factor for the function of 
TAL1 and that LMO1/2 and TAL1 share common oncogenic pathways in T-ALL.  
It has also been suggested that aberrant expression of TAL1 and LMO2 
inhibits the functions of E-protein homodimers essential for normal T cell 
maturation, leading to differentiation block of T cells (89). The phenotype of Heb-
null mice resembled that of Tal1 and Lmo2 transgenic mice during the pre-
leukemic stage (89). Structural studies revealed that TAL1:E47 heterodimer is 
more stable than E47 homodimer and that LMO2 binding to the heterodimer 
strengthens the interaction between TAL1 and E47 even more (257), supporting 
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the idea of HEB/E47 sequestration by TAL1 and LMO1/2. Interestingly, LMO2 
recruitment to the heterodimer weakened the affinity of protein binding to DNA 
(257). Thus other transcription factors would be critical for 
TAL1:E47:LMO1/2:LDB1 to form a regulatory complex and to stably occupy the 
target genomic loci. In fact, a DNA binding mutant of TAL1 was able to develop 
T-ALL in cooperation with LMO2 overexpression (87).  
TAL1 is a part of a transcriptional auto-regulatory circuit with RUNX1 and 
GATA3, activating the MYB oncogene in T-ALL 
 Formation of transcriptional regulatory circuits has been suggested in 
several cell types including embryonic stem cells and normal hematopoietic cells 
(258,259). In human T-ALL cell lines and patient samples, ChIP-seq studies 
followed by binding motif analyses found the ETS and RUNX binding motifs were 
highly enriched at TAL1 binding sites, in addition to the GATA binding motif, 
which is also found in erythroid cells (93,237). Consistently, ChIP-seq analyses 
for TAL1, HEB, E2A, GATA2, LMO1/2, and RUNX1 demonstrated that a large 
portion of genomic sites occupied by TAL1 are also bound by multiple 
transcription factors (237). The combined gene expression profiles of cells in 
which TAL1, RUNX1, or GATA3 are suppressed uncovered that the expression 
of direct target genes of TAL1, such as MYB, were also altered by GATA3 and 
RUNX1 depletion (237). Furthermore, it was observed that these transcription 
factors were bound to each other’s and their own regulatory regions suggesting 
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that the complex is autoregulated (237). Therefore, it appears that TAL1 is part of 
a large interconnected regulatory complex in T-ALL cells to reinforce the 
oncogenic downstream pathways.   
MYB is a transcription factor, essential for normal and malignant 
hematopoiesis (260) found highly expressed in hematopoietic stem and 
progenitor cells (HSPCs), and decreased during differentiation (261). Studies 
targeting Myb at different stages of T-cell development revealed that MYB is 
required for pre-TCR rearrangement at the DN stage, for the survival of DP cells, 
and for the differentiation of DP cells into SP cells (262). MYB was initially 
identified as a common retrovirus insertion site, associated with myeloid 
leukemia (263,264). In T-ALL, chromosomal translocation with the TCRb 
enhancer or Alu element-mediated duplication resulted in aberrant expression of 
MYB (146,265,266). In addition, overexpression of v-Myb induced T-ALL in mice 
(267) while MYB silencing released the differentiation block and impeded the 
growth of T-ALL cell lines (266), suggesting an oncogenic role of MYB in human 
T-ALL.  
ChIP-seq and gene expression studies showed that MYB is a direct target 
gene of the TAL1 regulatory complex and that MYB contributes to the oncogenic 
gene expression program of TAL1 in T-ALL (237). The recent finding of 
mutations in the upstream region of TAL1 allowing MYB binding indicated that 
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MYB is also a component of the TAL1 interconnected auto-regulatory complex 
(234). 
Controversial roles of RUNX1 in leukemogenesis 
 RUNX1 is one of the most commonly mutated genes in hematopoietic 
malignancies (33). Most genes associated with tumorigenesis are classified as 
oncogenes or tumor suppressors; however, RUNX1 has been found to perform 
both functions depending on the cell type. The involvement of RUNX1 in 
leukemia was first discovered by identification of chromosomal translocation 
t(8;21) creating RUNX1-RUNX1T1/EPT gene, encoding AML1/RUNX1-ETO, 
which is the most frequent mutation in AML (268). Subsequently, several types of 
translocations and somatic point mutations affecting the RUNX1 gene have been 
identified in AML, myelodysplastic syndrome (MDS), and ALL (33,269–273). 
AML1/RUNX1-ETO functions as a dominant negative inhibitor against the normal 
RUNX1 protein or reduces its activity, suggesting that loss of function of RUNX1 
is associated with hematopoietic malignancy (270,273–276). The tumor 
suppressor roles of RUNX1 have been supported by findings of germline 
monoallelic RUNX1 mutations in familiar platelet disorder (FPD) with 
predisposition to AML (277–279). On the other hand, overexpression of RUNX1 
in leukemic cells has suggested that RUNX1 can function as an oncogene. First, 
the promoter region of the RUNX1 gene was a frequent site of retroviral insertion 
in lymphoid leukemias in mice (280–283) and as result, the expression of the 
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whole intact gene was increased in leukemic cells (283). In addition, the 
overexpression of RUNX1 resulting from the amplification of a large region of 
chromosome 21 has been observed in a subset of B-ALL associated with a poor-
prognosis and in few AML cases (284–288). A remarkable number of B-ALL 
patients exhibit upregulated RUNX1 even in the absence of chromosomal 
amplifications (289).  
The ability of RUNX1 to either activate or repress the transcription of 
critical regulators of cell differentiation and growth can explain the contrasting 
roles of RUNX1 in leukemogenesis. In addition, the fact that the deregulation of 
RUNX1 can result in different cell lineages argues for cell-type dependent roles 
of RUNX1. Indeed, the enforced expression of RUNX1-ETO in stem cells 
resulted in expansion of myeloid cell lineage and myeloproliferative disorder 
(290,291). However, expression of the transgene was not detected in lymphoid 
cells, probably due to the adverse effects of the fusion protein on lymphoid cell 
survival and development (290). Furthermore, administration of DNA-alkylating 
mutagen N-ethyl-N-nitrosourea (ENU) resulted in AML development in RUNX1-
ETO expressing mice, in contrast to ALL development in wild type RUNX1 
expressing mice (292).  
RUNX1 deregulation results in the development of myeloid malignancy 
In addition to the t(8;21) translocation, more than 50 cases of 
chromosomal translocation including t(3;21)(q26;q22), which results in RUNX1-
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MECOM (MDS1-EVI1), have been found in malignant hematopoietic cells 
(269,293). Most of the translocations affecting the RUNX1 gene have been 
observed in AML or MDS (33,269). One of the predominant translocations 
t(12;21) prevalent in B-progenitor ALL (B-ALL), creates a TEL1-RUNX1 fusion 
protein (294–296). The resulting fusion protein contains the RUNT domain with 
or without other domains of RUNX1 and parts of or entire other proteins 
(33,268,293,296). These fusion proteins can bind to RUNX binding sites while 
interacting with coactivators such as p300 and protein arginine methyltransferase 
1 (PRMT1) (297,298), or corepressors such as NCOR1, HDAC1, and SIN3A 
(275,276,299), in different ways than normal RUNX1 (274), resulting in altered 
gene regulation. In addition, the fusion proteins interfere with the function of other 
transcription factors by direct interaction. For example, RUNX1-ETO binds with 
and inhibits CCAAT/enhancer binding protein alpha (CEBPA) and PU.1, which 
are critical transcription factors for myeloid development, leading to myeloid 
leukemia development (300–302). 
Besides the abnormal chromosome rearrangements, monoallelic or 
biallelic somatic mutations of the RUNX1 gene have been identified in AML and 
MDS (270,273,303,304). MDS patients with RUNX1 mutations are at greater risk 
for the progression to AML and that AML patients with RUNX1 mutations have a 
worse prognosis compared with patients harboring wildtype RUNX1 (305–309). 
Identified mutations include missense mutation, nonsense mutations, and frame-
shift mutations, and are mainly distributed in the RUNT domain, predicted to 
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result in reduced RUNX1 transcriptional activity (271,305–307). Gene expression 
analyses revealed that RUNX1 mutations in AML resulted in a distinct gene 
expression profile with deregulated genes involved in apoptosis, upregulated 
lymphoid regulator genes, and downregulated of genes required for myelopoiesis 
genes (307,309,310), indicating that RUNX1 abnormalities can lead to 
differentiation defects.   
Several activating mutations of signal transduction pathways leading to 
cell survival and proliferation have been observed in RUNX1 mutated AML (305–
307,309,310). FLT3-internal tandem duplication (ITD), FLT3-tyrosine kinase 
domain mutation (TKD), MLL-partial tandem duplication (PTD) and mutations in 
NRAS, IDH1/2, and KIT were highly associated with RUNX1 mutations in AML. 
Therefore, it seems that the differentiation block due to mutations in RUNX1 work 
together with mutations imparting growth advantage in order to promote AML 
development. In addition, mutations in epigenetic regulators such as ASXL1/2 
and DNMT3A were also frequently associated with RUNX1-deregulated AML 
(309,311,312).   
The oncogenic potency of RUNX1-fusion proteins or mutations in RUNX1 
have been shown experimentally using in vivo and in vitro systems. Mice 
reconstituted with BM cells transduced with retrovirus that expresses 
RUNX1-MECOM, RUNX1-ETO or mutated RUNX1 all develop AML 
(291,313,314). RUNX1-ETO transgenic mice expressing the fusion gene in 
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progenitor cells under the Sca-1 promoter also recapitulated the development of 
myeloid leukemia (290). Ectopic expression of RUNX1-ETO in CD34+ human 
progenitor cells induced cell growth while retaining progenitor characteristics, and 
inhibited the differentiation (315,316), in agreement with the hypothesis that 
RUNX1 mutants may disturb the balance between differentiation and self-
renewal.  
Mutations of CBFb, a heterodimeric partner of RUNX proteins, are also 
frequent in AML. Inversion of chromosome 16, inv(16)(p13q22), produces a 
fusion gene of CBFb and with the MYH11 (a smooth-muscle myosin-heavy-chain) 
gene (317). The resulting fusion protein binds to RUNX1 with higher affinity than 
wildtype CBFb, inhibiting RUNX1 function and inducing AML development 
(318,319). The phenotypes of  inv(16) knock-in mouse, which are similar to those 
of the Runx1-null mouse, provide evidence of dominant-negative function of the 
fusion protein (320).     
RUNX1 is a potential tumor suppressor in certain subtypes of T-ALL 
While RUNX1 deregulation has been intensively investigated in myeloid 
leukemia, its association with T-ALL has been less clear. Recent whole genome 
sequencing studies identified mutations of the RUNX1 gene in about 15% of 
ETP-ALL cases (131,150,321,322). These mutations include chromosomal 
translocations affecting the RUNX1 gene, heterozygous missense mutations, 
nonsense mutations, frame-shift mutations, and in-frame insertion mutations 
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(131,321,323). Similar to those identified in AML, most of the mutations besides 
chromosome alterations were mapped on the RUNT domain and the 
transactivation domain, and presumably result in loss-of-function of RUNX1 
(150,321,323), indicating that normal RUNX1 activity suppress thymocyte 
transformation.  
Tumor suppressor roles of RUNX1 were invoked in TLX1/3-positive early 
cortical T-ALL subtype (323). The gene expression profile revealed that TLX1 
and TLX3 function to directly repress RUNX1 expression. In agreement with this, 
overexpression of RUNX1 by retroviral transduction in TLX1- or TLX3-positive 
human T-ALL cell lines inhibited cell growth (323). However, studies of the role of 
RUNX1 in other subtypes of T-ALL have suggested that RUNX1 has oncogenic 
functions (93,237,324). 
RUNX1 activation promotes T-ALL development 
ChIP experiments for NOTCH1 or TAL1 performed in human T-ALL cell 
lines to investigate the mechanism of TAL1 and NOTCH1 regulation in T-ALL 
first identified the RUNX binding motif was the one of the most representative 
sequences in NOTCH1 or TAL1 binding sites (88). Subsequent studies found 
that RUNX1 actually binds 74% of NOTCH1 and 78% of TAL1 binding loci  
(237,324), indicating that RUNX1 regulates a subset of NOTCH1 and TAL1 
regulated genes. Gene expression analysis showed that a large number of TAL1 
target genes were also regulated by RUNX1, thus confirming the cooperation 
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between RUNX1 and TAL1 (237). RUNX1 was suggested to be a component of 
the TAL1 interconnected regulatory complex, which was observed in primary 
T-ALL patient samples as well (234,237). These results raise a possibility that 
RUNX1 plays oncogenic roles in T-ALL development, which I have studied in this 
thesis research. 
Abnormal transcriptional programs in cancer cells.  
As described earlier in cases of TAL1, NOTCH1, and RUNX1 in 
leukemogenesis, dysregulation of transcription factors and subsequent gene 
expression are hallmarks of cancer. Transcription factors bind to regulatory 
elements composed of promoters, enhancers, and silencers in a sequence-
specific manner. They recruit transcription machinery, cofactors (MED1, SMC3), 
and chromatin regulators, such as chromatin remodeling complexes (SNI/SNF 
complexes), and histone modifying enzymes (SET1, MLL, and DOT1L) to DNA 
and regulate gene expression (326,327). A subset of transcription factors has 
been shown to be sufficient to induce cell type-specific gene expression 
programs and define cell states (328–332). In committed immature T-cells, 
ectopic expression of C/EBPa and PU.1 can redirect cells to macrophages and 
dendritic cells, respectively (332). These transcription factors, known as mater 
transcription factors, are highly expressed in certain cell types and typically 
regulate their own expression through an autoregulatory loop (237,333). Thus, 
dysregulation of master transcription factors in tissues can alter cell identity and 
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induce tumorigenesis. In addition, abnormal regulation of transcription factors 
involved in cell proliferation and amplification of transcriptional output, such as 
MYC (334,335) and other signaling pathways that cooperate with master 
transcription factors, can promote transformation (336,337). Besides transcription 
factors, aberrant cofactors, such as mutated MED12 (a mediator complex 
component), also contribute to cancer-associated transcription (338,339).  
Among the regulatory elements, enhancers are associated with cell type-
specific genes and bound by multiple transcription factors (340). Enhancers have 
been mapped by epigenetic marks associated with enhancer activity, including 
acetylated lysine residues of histone 3 and histone 4 tails (H3K27ac and H3K9ac) 
or di/tri-methylation of H3K4 (H3K4me2 and H3K4me3) (341). Among them, 
super-enhancers are large clusters of transcriptional enhancer elements 
regulating the expression of genes that determine cell identity (340,342). They 
are occupied by high levels of multiple different master transcription factors, the 
Mediator complex, chromatin regulators, and polymerase II to ensure significant 
expression of associated genes (342). Polymerase II that is bound to super-
enhancers produces non-coding enhancer RNAs (eRNAs) that mediate the 
maintenance and activities of enhancers (343,344). In addition, enhancer loci 
exhibit disease-associated sequence variations (345,346). In cancer cells, it has 
been shown that driver oncogenes are associated with cancer type-specific 
super-enhancers, which are not present in healthy cell counterparts, and highly 
vulnerable to perturbation (340,347). Cancer cells acquire super-enhancers by 
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DNA translocation (348–350), focal amplification (351–353), small 
insertion/deletions of nucleotides (251), and overexpression of oncogenes (340).   
MYC is regulated by super-enhancers in cancer cells 
Recently, it has been reported that MYC is regulated by super-enhancers 
in cancer cells. In T-ALL, a super-enhancer controlled by NOTCH1 is located 
1.47 Mb downstream from the MYC transcription start site (TSS) (N-Me) (351). 
The focal duplication of this region was found in T-ALL patient samples, 
specifically. The binding of NOTCH1, P300, and active histone marks, such as 
H3K27ac and H3K4me1 (monomethylation), at this locus was highly and 
specifically enriched in T-ALL cells indicating that this region is particularly active 
in T-ALL (351). In addition, this enhancer is required for the development of 
normal thymocytes as well as T-ALL initiation and maintenance in mice (351). 
Chromosome conformation capture (3C) experiments uncovered that this distal 
enhancer regulates MYC expression by a chromatin loop formation between the 
enhancer and promoter region of MYC (208,351).  
In GSI-resistant persister T-ALL cells, MYC appears to be expressed by 
another long-range enhancer located at 1.7 Mb downstream from the MYC TSS 
in a NOTCH1-independent manner (207). BRD4, which is required for the 
survival of persister cells, newly bound at this enhancer region (BDME, BRD4 
dependent MYC enhancer) in persister cells (208). Chromatin loop formation 
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between the MYC TSS and BDME was maintained, while the interaction of MYC 
TSS with N-Me was disrupted in persister cells (208). 
Super-enhancers driving MYC expression have been identified in other 
types of cancer. In AML cells, MYC expression is regulated by BDME which is 
amplified in AML patient samples (352,354,355). BRG1, a component of 
SWI/SNF chromatin remodeling complex binds to this enhancer and regulates 
expression of MYC through controlling the interaction between the promoter and 
enhancer loci (352). Several transcription factors including CEBPa/b, ERG, PU.1, 
and LMO2, and BRD4 bind to this enhancer locus (352). Comprehensive single-
nucleotide polymorphism (SNP) arrays in colorectal, breast, prostate, and 
ovarian cancer cells uncovered sequence variations within the upstream region 
of the MYC gene which contains a large number of enhancer elements (356–
358). Individual enhancers within this region physically interact with the MYC 
promoter region in a tissue-specific way (359). The rs6983267 SNP at 335 kb 
upstream of the MYC gene in colon cancer cells results in increased TCF4 
(transcription factor 4) binding and modification of active histone marks, leading 
to MYC upregulation (360). In addition, mice with a 538-kb deletion of the 
upstream region of the Myc gene are resistant to tumorigenesis while they do not 
exhibit developmental defects (361). 
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MYB expression is controlled by long-distance range locus.  
 Expression of the MYB gene is regulated by binding of transcription 
factors at its promoter regions, including MYB itself and PU.1 (362,363). In 
addition, a locus control-like region controlling MYB expression in mice was 
identified approximately 77 kb upstream from the Myb gene (260). Recent ChIP-
seq analyses revealed that not only this locus but also other regions, including 14 
kb downstream and 93 kb upstream from the MYB gene, are bound by several 
transcription factors including TAL1, GATA3, LMO2, and HEB in T-ALL cells 
(237). In addition, the active histone mark H3K27ac is highly enriched at these 
regions suggesting these regions contain enhancer elements (364). In fact, 
distribution analyses of H3K27ac signals in T-ALL cells indicated that MYB is 
associated with a super enhancer stretched around the MYB gene (340,364). 
The binding of MED1, a coactivator enriched in super-enhancer regions, is also 
abundant around these regions (234).  
 In the research presented in this thesis, I investigated roles of RUNX1 in 
T-ALL pathogenesis. Based on the overlapping occupancy of RUNX1 with the 
TAL1 complex and NOTCH1, I hypothesize that RUNX1 functions as an 
oncogene in T-ALL development and interrogated the effects of RUNX1 
suppression in T-ALL progression. I focused on roles of RUNX1 in transcriptional 
regulatory elements to advance the understanding of the molecular mechanisms 
in T-ALL development. 
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Figure 1.1. Thymocytes development. Early thymic progenitor cells (ETPs), 
differentiated from HSCs, are immigrated from the BM. Thymocytes travel in the 
thymus and differentiate while losing potentials for other lineages. Thymocytes 
change cell surface marker profiles during the differentiation. (Adapted from 
E.V.Rothenberg 2008 Nature Review Immunology 8:9-21)   
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Figure	1.2.	The	structure	of	RUNX	proteins.	The	RUNX	family	comprises	RUNX1,	2	and	3	
proteins.	 They	 share	 the	 highly-conserved	 RUNT-homology	 domain	 (RHD)	 and	 the	 C-
terminal	 VWRPY	motif.	 All	 three	 proteins	 have	 the	 transactivation	 domain	 (TAD),	 the	
inhibitory	 domain	 (ID),	 and	 a	 nuclear-matrix-targeting	 signal	 (NMTS).	 Only	 RUNX2	
protein	 has	 the	 extended	 glutamine-alanine	 repeat	 domain	 (QA)	 at	 N-terminus.	 The	
numbers	of	amino-acid	refer	human	RUNX	proteins. 
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Chapter II 
RUNX1 and/or RUNX3 is required for  
T-ALL survival 
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Introduction 
 It has been demonstrated that suppression of RUNX1 functions to 
promote T-ALL pathogenesis, similar to its function in AML. Loss of function 
mutations in RUNX1 are enriched in the ETP-ALL subtype and are associated 
with poor prognosis (131,321,323). In addition, in TLX1/3-transformed T-ALL 
cells, disruption of the RUNX1 transcriptional network by TLX1/3 was proposed 
as a key mediator of T-ALL development, and overexpression of RUNX1 in these 
leukemic cells impairs growth (323).  
In contrast, RUNX1 has also been suggested to support functions of 
dominant oncogenes in T-ALL. In human T-ALL cell lines and patient samples, 
TAL1 comprises a core transcriptional regulatory complex with RUNX1 and 
GATA3 (237). In addition, ChIP-seq studies for NOTCH1 and RUNX1 have 
revealed that RUNX1 binds to most of the same genomic loci where NOTCH1 is 
bound (324). These data indicate that RUNX1 contribute to TAL1- or NOTCH1-
mediated leukemogenesis. 
To elucidate whether RUNX1 potentiates or suppresses T cell 
leukemogenesis, we generated Tal1/Lmo2/Rosa26-CreERT2Runx1f/f mice that 
develop TAL1-induced T-ALL and acquire spontaneous mutations in NOTCH1 
(175), and reveal a crucial, pro-survival role for RUNX1 in T-ALL. Similarly, we 
demonstrate that RUNX1/3 knockdown in human T-ALL cell lines or treatment 
with a recently developed CBFβ/RUNX allosteric inhibitor mimics the effects of 
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Runx1 deletion in mouse T-ALL cells and induces apoptosis. These data provide 
genetic and pharmacologic evidence that RUNX1 has critical survival roles in T-
ALL and support the idea that RUNX1 inhibition may have therapeutic benefit for 
T-ALL patients. 
Results 
RUNX activity is required for the growth and survival of T-ALL cells.  
 To examine roles of RUNX1 in T-ALL pathogenesis, we generated 
Tal1/Lmo2/Rosa26(R26)-CreERT2Runx1f/f mice and transplanted mouse 
leukemic cells into secondary recipients. One week after the transplantation for 
leukemic cells to be engrafted, mice were treated with vehicle or tamoxifen to 
delete Runx1 alleles (Figure 2.1A). As results, we observed that Runx1 deletion 
interfered with or prevented leukemic growth in vivo (Figure 2.1B). Notably, the 
few Tal1/Lmo2/R26-CreERT2Runx1f/f mice that developed disease (5568 and 
7714) retained a floxed Runx1 allele that likely escaped Cre-mediated deletion in 
vivo (Figure 2.1C). Consistently, Runx1 deletion induced by 4-OHT treatment in 
vitro (Figure 2.2A,B) resulted in apoptosis of mouse T-ALL cells (Figure 2.2C). To 
rule out any potential effects of tamoxifen- or Cre-mediated toxicity on 
leukemogenesis, we generated Tal1/Lmo2/R26-CreERT2 mice and treated them 
with vehicle or tamoxifen, but observed no significant effects on disease 
progression or leukemic cell survival (Figure 2.3A,B). Collectively, these data 
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indicate that RUNX1 is required for T-ALL maintenance in vivo and for leukemic 
cell survival in vitro.  
During mouse thymocyte development, RUNX1 is expressed in immature 
DN and DP thymocytes, whereas RUNX3 expression becomes distinct later in 
more mature CD8 single positive (SP) thymocytes (365). Consistently, we found 
RUNX1 expressed predominantly in mouse DP leukemic cells, with no RUNX3 
protein expression detected (Figure 2.3C), thereby explaining the RUNX1 
dependency observed in mouse T-ALL.  
Depletion of RUNX1/3 or CBFb in vitro results in apoptosis of human 
leukemic cells. 
To determine whether human T-ALL cells were similarly RUNX1-
dependent, we first examined CBFβ, RUNX1 and RUNX3 expression in human 
T-ALL cell lines and primary patient samples (Figure 2.4A,B). All of the human T-
ALL cell lines examined expressed CBFβ and most expressed RUNX1, with low 
to undetectable levels of RUNX3 (Figure 2.3C). However, RUNX1 and RUNX3 
were co-expressed in KOPTK1 and LOUCY cell lines and in 5 of 8 primary 
pediatric T-ALL samples examined (Figure 2.4A,B). We reduced RUNX1 
expression in human T-ALL cell lines (Jurkat, KOPTK1, PF382 and RPMI8402) 
by expressing 2 independent RUNX1-specific shRNAs and, as reported 
previously (237), observed significant increases in apoptotic cells (Figure 2.5A-C). 
We also investigated RUNX3-dependency in KOPTK1, Jurkat, and RPMI8402 
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cell lines. Consistent with the expression data, RUNX3 reduction induced 
significant cell death in KOPTK1 cells, but not in the Jurkat cell line (Figure 
2.5D,E), indicating that when they are expressed, both RUNX1 and RUNX3 can 
support the survival of human T-ALL cell line. Knockdown of CBFβ, the binding 
partner of RUNX proteins, also induced apoptosis (Figure 2.5F,G), revealing pro-
survival roles for the CBFβ/RUNX1 and CBFβ/RUNX3 heterodimer in TALL.  
CBFb/RUNX inhibition induces apoptosis of human T-ALL cells and patient 
samples. 
The observation that RUNX1 and/or RUNX3 are required for the survival 
of mouse and human leukemic cell suggests that RUNX proteins could be 
potential therapeutic targets in T-ALL. The Bushweller laboratory developed a 
series of small molecule inhibitors designed to interfere with CBFβ binding to 
RUNX proteins, thereby leaving them in an auto-inhibited state (366); the 
inhibitor AI-10-104 is a potent derivative among them (Figure 2.6A). AI-10-104 
treatment induced a dose-dependent decrease in the CBFβ/RUNX1 and 
CBFβ/RUNX3 heterodimers detected in human T-ALL cells without detectable 
effects on CBFβ, RUNX1 or RUNX3 protein levels (367). These data confirm that 
the AI-10-104 inhibitor interferes with the formation of the CBFβ/RUNX1 and/or 
CBFβ/RUNX3 heterodimers and suggest that AI-10-104 impedes the function of 
RUNX proteins in T-ALL cells. Consistent with the RUNX1/3 or CBFb depletion 
data, treatment of human T-ALL cell lines with AI-10-104 induced apoptosis in a 
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dose dependent manner, whereas treatment with 10μM of the inactive analogue 
AI-4-88 had no effect on leukemic growth or viability (Figure 2.6B,C). Notably, 
LOUCY ETP-ALL cells which do not express TAL1 or mutant NOTCH1 (Table 
2.1) were resistant to AI-10-104 treatment (Table 2.2: GI50 = 11μM). 
We also examined primary pediatric T-ALL samples for their sensitivity to 
the CBFβ/RUNX inhibitor AI-10-104. Treatment of diagnostic and relapsed 
pediatric T-ALL samples with AI-10-104 in vitro inhibited the cell growth with an 
average GI50 of 2.4μM (Figure 2.6E) and induced apoptosis (Figure 2.6G,H), 
whereas treatment with the inactive compound AI-4-88 had no effect on the 
growth/viability of primary T-ALL samples (Figure 2.6D,H). Moreover, AI-10-104 
sensitivity correlated with RUNX1/3 expression levels in 7 of 8 T-ALL patient 
samples selected at random (Figure 2.6F). 
RUNX1 is required for hematopoietic stem and progenitor cell 
development and survival (56,57) raising the possibility that RUNX inhibition in 
leukemic patients may result in on target effects on normal hematopoietic stem 
and progenitor cells. We performed dose response studies on bone marrow 
samples from 3 independent healthy donors. Treatment of normal human 
hematopoietic cells with AI-10-104 resulted in an average GI50 of 15.4μM (Figure 
2.7F), which exceeded the average GI50 observed for primary patient leukemic 
samples by 7-fold. Unfortunately, the pharmacokinetics of the current AI-10-104 
inhibitor preclude its preclinical testing in vivo. Nonetheless, these data suggest a 
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therapeutic window may exist for optimized derivatives of AI-10-104 in T-ALL 
patients. 
RUNX dependency extends to TAL1-negative, TLX3-transformed human T-
ALL cells.  
Unexpectedly, the RUNX inhibitor AI-10-104 induced cell growth arrest 
and apoptosis in the TAL1-negative T-ALL cell lines including TALL-1, HPB-ALL 
and DND-41 (Figure 2.6B, (367)). HPB-ALL and DND41 cell lines are TLX3-
transformed T-ALL cells, where RUNX1 was proposed to function as a tumor 
suppressor (323). To validate the inhibitor results, we investigated the reliance of 
HPB-ALL cells on RUNX1 genetically. We transduced HPB-ALL cell lines with 
lentiviruses expressing shRNA against GFP control or RUNX1 and observed that 
reduction of RUNX1 expression significantly induced leukemic cell apoptosis 
(Figure 2.8), which supports the inhibitor data. These results indicate that RUNX1 
is required for the survival of T-ALL cells in the absence of the cooperation with 
TAL1, and that RUNX1 might be oncogenic in TLX3-positive T-ALL cells.  
Discussion 
 We provide genetic evidence that RUNX1/3 have crucial pro-survival roles 
in T-ALL in vivo and in vitro even in TAL1-negative T-ALL cells. In addition, we 
showed that RUNX proteins can be targeted by using a small molecule inhibitor 
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interfering with CBFb binding to RUNX proteins in order to inhibit T-ALL 
pathogenesis.     
 Our data are supported by the demonstration that a recently developed 
CDK7 inhibitor (THZ1) exhibited selectivity for human T-ALL cells and was 
shown to act via suppression of the RUNX transcriptional network (364). 
Although CDK7 is a component of the general transcription factor IIH (TFIIH) 
complex, low dose THZ1 treatment of human T-ALL cells affected the 
transcription of a subset of genes; with RUNX1 expression most profoundly 
affected.  
 Importantly, we demonstrate that the pro-survival roles for RUNX1 
revealed in our mouse TAL1/LMO2 T-ALL model translate to human T-ALL cells 
transformed by TAL1, TLX3 and/or NOTCH1. We hypothesize that RUNX1 
supports TLX3-transformed cells through interaction with activating NOTCH1 in 
HPB-ALL, which will be discussed in Chapter 3. What remains unclear is whether 
T-ALL cells that do not express TAL1 or activated NOTCH1 also depend on the 
RUNX transcription factors for survival. We attempted to address this issue in 
LOUCY cells (TAL1- and NOTCH1-negative), which proved relatively resistant to 
AI-10-104 treatment (Table 2.2), suggesting that the TAL1 and/or NOTCH1 
status determines the RUNX dependency. Based on the prevalence of TAL1 and 
NOTCH1 activation in T-ALL, we expect most T-ALLs to be sensitive to RUNX 
inhibition. Consistent with our findings, Jenkins et al., found mouse T-ALLs 
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transformed by activated NOTCH1 and all human T-ALL cell lines examined 
(n=15) depend on RUNX1 for their survival (Catherine Jenkins and Andrew 
Weng, manuscript submitted 2017). 
 Since RUNX1 is involved in T-cell development, we targeted RUNX1 in 
fully transformed leukemic cells and demonstrated that RUNX1 supports the 
maintenance of leukemia. However, whether RUNX1 is required for T-ALL 
initiation remains to be determined. A previous study that indirectly repressed 
RUNX1 by NOTCH1 in leukemia-initiating or stem cell population (368) implies 
that the role of RUNX1 in T-ALL initiation might not be the same as the role it 
plays in the maintenance of leukemia. In line with this, ENU treatment of chimeric 
Runx1-deficient mice (Runx1lacZ/lacZ) induced T-ALL suggesting that Runx1 
depletion predisposes progenitor cells to leukemia (369). However, it is not clear 
how Runx1-deficient cells differentiate into the lymphoid lineage to give rise to 
leukemia. Thus, it would be worth targeting RUNX1 in developing T-cells, for 
example ablating Runx1 floxed alleles using Lck-cre, to clearly define RUNX1 
contribution to leukemia initiation. 
Methods and Materials 
Mice A cohort of Tal1/Lmo2/Rosa26(R26)-CreERT2Runx1f/f mice was generated 
by mating Tal1/Lmo2 mice with Rosa26-CreERT2Runx1f/f mice. 
Tal1/Lmo2/Rosa26-CreERT2Runx1f/f leukemic cells were transplanted into F1 
(FVB/N x C57BL/6J) recipient mice and corn oil (Sigma, C-8267) or Tamoxifen 
	 
59 
(1mg Sigma, T-5648) was intraperitoneally injected for 3 days one week after 
transplantation. All animal procedures performed in this study were approved by 
the University of Massachusetts Medical School Institutional Animal Care and 
Use Committee. 
Primary mouse and patient T-ALL cells and cell lines. Mouse 
Tal1/Lmo2/R26-CreERT2Runx1f/f T-ALL cells were treated with ethanol or 5 or 
10 nM of 4-OHT (Sigma) for 24 hours, washed with PBS, and cultured for 1 or 
2 days prior to further analyses. Primary human T-ALL samples were obtained 
from children with T-ALL enrolled in clinical trials at the Dana-Farber Cancer 
Institute or collaborating Institutions, or from the University of Massachusetts 
Memorial Hospital. Samples were collected with informed consent and with 
approval of the institutional review board. Leukemic blasts were isolated from 
peripheral blood or bone marrow as previously described (207).  
RUNX and CBFb silencing. The lentiviral pLKO.1-puro vectors carrying shRNA 
targeting RUNX1 and RUNX3 were generously provided by Dr. Marjorie Brand 
(Ottawa Hospital Research Institute). The lentiviral pLKO.1-CBFb vectors were 
purchased from the shRNA core at University of Massachusetts Medical School. 
Viruses were generated and human T-ALL cell lines infected as previously 
described (93). The level of knockdown was determined using qRT-PCR and 
immunoblotting 4 days after infection. 
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Cell viability and death assays. Human T-ALL cell lines or T-ALL patient 
samples were cultured for 3 days in the presence of DMSO or various 
concentrations of AI-10-104 or AI-4-88. Metabolic activity was assayed by MTS 
cell proliferation colorimetric assay (CellTitre96 AQueous One Solution Cell 
Proliferation Assay, Promega) or CellTiter-Glo (CellTiter-Glo Luminescent Cell 
Viability Assay, Promega) and measured using a Beckman Coulter DTX880 plate 
reader. Absorbance values were normalized to DMSO control. Human T-ALL cell 
lines transduced with lentiviruses or treated with AI-10-104 or AI-4-88 were 
stained with Annexin V-FITC and 7AAD to detect apoptotic cells and with anti-
CD4 antibody, and analyzed by flow cytometry.  
Genomic DNA and RNA analyses. Total RNA was extracted using Trizol and 
cDNA was synthesized using Superscript First-Strand Synthesis System 
(Invitrogen). Quantitative realtime PCR assays were performed using the 
AB7300 Detection System (Applied Biosystem) using POWER SYBR Green 
Master Mix (Applied Biosystem) and gene specific primers. Gene expression was 
determined using the ΔΔCT method normalized to GAPDH for human or β-Actin 
for mouse transcripts, unless otherwise specified. Using isolated genomic DNA, 
Runx1 deletion was determined by PCR as described previously (57). 
Immunoblotting. To examine protein expression in human T-ALL cells, cells 
were lysed in modified radioimmunoprecipitation assay (RIPA) buffer, transferred 
to a membrane, and probed with antibodies to RUNX1 (ab23980, Abcam), 
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RUNX3 (MAB3765, R&D System), TAL1 (sc-12984, Santa Cruz), MYB (05-175, 
Millipore), NOTCH1 (Val1744, Cell signaling), MYC (N262, Santa Cruz), or 
ERK1/2 (9102, Cell Signaling). Blots were imaged using ImageLab Software 
(Bio-Rad).   
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Figure 2.1. RUNX1 is required for the maintenance of leukemic growth in 
vivo. (A) Experimental strategy used to determine the effects of Runx1 deletion 
on leukemia progression in vivo. Three independent mouse T-ALLs from 
Tal1/Lmo2/R26-CreERT2 Runx1f/f mice were transplanted into mice and treated 
with vehicle or tamoxifen one week later for 3 days. (B) Kaplan-Meier survival 
curves are shown for 3 mouse T-ALLs and the difference in overall survival 
between	vehicle and tamoxifen treated groups assessed by the log-rank test (n=4 
for Vehicle, n=6 for Tam group in all 3 experiments). (C) Mice that develop 
disease derive from T-ALL subclones that retain the floxed Runx1 allele. For the 
control samples, genomic DNA was isolated from tail biopsies of wild type, 
Runx1f/+ and Runx1f/f mice (designated WT, F/+ and F/F). For the deleted control, 
DNA was isolated from mouse T-ALL cell line 1143, which was derived from a 
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leukemic Tal1/Lmo2/R26-CreERT2Runx1f/f mouse that was treated with 4-OHT in 
vitro for 48h (designated F/D). Analysis of primary mouse T-ALL 7714 reveals a 
Tal1/Lmo2/Rosa26-CreERT2Runx1f/D genotype likely due to leaky Cre expression 
in the primary tumor. DNA was isolated from untreated mouse T-ALL 7714 cells 
(UN) and from tumor tissue isolated from transplanted mice at the time of 
sacrifice. V1 and V2 refers to tumor DNA isolated from 2 independent vehicle 
treated mice transplanted with mouse T-ALL 7714 cells. The WT band likely 
reflects the presence of normal cells in the tumor specimen. T1 and T2: Tumor 
DNA isolated from 2 independent tamoxifen treated mice transplanted with 
mouse T-ALL 7714 cells. These tamoxifen-treated mice succumbed to disease 
and selected for leukemic clones that retained the floxed Runx1 allele. M 
indicates DNA ladder used to estimate fragment size.	
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Figure 2.2. RUNX1 supports survival of mouse leukemic cells in vitro. 
(A) Experimental strategy used to determine the effects of Runx1 deletion on 
mouse T-ALL survival in vitro. (B) Genomic DNA was isolated from mouse T-ALL 
cells 48 hours after EtOH or 4-OHT treatment to examine Runx1 deletion by 
genomic PCR. (C) Mouse T-ALLs (1143 and 9895) were treated with vehicle or 
4-OHT for 72 hours, stained with Annexin V-FITC and 7-AAD, and analyzed by 
flow cytometry. The quantification of Annexin-V positive cells from 4 independent 
experiments is shown as means ± SD (right) (*p<0.05, **p<0.005, ***p<0.0005 
Two-way ANOVA multiple comparisons test). 
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Figure 2.3. Cre activation has no significant effects on mouse T-ALL growth 
in vitro and RUNX3 protein expression in mouse leukemic cells. (A) Mouse 
T-ALL cells from Tal1/Lmo2/R26-CreERT2 mice were transplanted into F1 mice 
and one week later tamoxifen was administered for 3 days. The survival curves 
for 3 mouse T-ALLs (1353, 4456 and 2716) were estimated using the Kaplan-
Meier method. (B) The 2 independent Tal1/Lmo2/R26-CreERT2 mouse T-ALL 
cells were treated with vehicle (EtOH) or 4-OHT and the apoptotic cells were 
determined by Annexin V-FITC and 7AAD staining followed by flow cytometry. 
The averages of 3 to 4 independent experiments are shown as mean ± SD. (C) 
RUNX1 and RUNX3 expression levels in mouse thymus and Tal1/Lmo2 mouse 
T-ALL cell lines were analyzed by immunoblotting. ERK1/2 was used as a 
loading control. 
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Figure 2.4. RUNX1, but not RUNX3, is ubiquitously expressed in human T-
ALL cell lines and primary patients T-ALL samples. (A) Protein was isolated 
from human T-ALL cell lines and RUNX1, RUNX3, CBFβ, TAL1, MYB, NOTCH1, 
and MYC protein levels were determined by immunoblotting. ERK1/2 was used 
as a loading control. (B) RUNX1 and RUNX3 expression in Jurkat, KOPTK1, and 
8 T-ALL patient samples were analyzed by immunoblotting. ERK1/2 was used as 
a loading control. 
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Figure 2.5. Knockdown of RUNX1, RUNX3, and CBFb results in apoptosis. 
(A) Jurkat, KOPTK1, RPMI8402, and PF382 human T-ALL cell lines were 
infected with lentiviruses expressing control shRNA or 2 shRNAs specific for 
RUNX1. RUNX1 mRNA and protein levels were examined by real time 
quantitative PCR and immunoblotting. (B) RUNX1 knockdown results in 
apoptosis of leukemic cells. Control (GFP) and RUNX1 shRNA transduced 
human cell lines were stained with Annexin V-FITC and 7AAD and analyzed by 
flow cytometry 6 days after infection. The percentage of apoptotic cells was 
determined by Annexin V/7AAD staining and analyzed by flow cytometry. Four 
independent experiments were performed, and data are shown as mean ± SD. 
(C) A representative cell death flow profile of the Jurkat cell line is shown. (D) 
RUNX3 mRNA levels in KOPTK1, Jurkat, and RPMI8402 cells transduced with 
control (GFP) or RUNX3-specific shRNA were measured by qRT-PCR. RPS9 
was used for normalization. (E) Apoptotic leukemic cells upon RUNX3 
knockdown in KOPTK1, Jurkat, and RPMI8402 human T-ALL cells were 
determined by Annexin V-FITC/7-AAD staining followed by flow cytometry. (F) 
CBFβ knockdown also induces apoptosis. Control (GFP) or CBFβ shRNA 
transduced Jurkat cells were stained with Annexin V-FITC and 7AAD and 
analyzed by flow cytometry. Four independent experiments were performed, and 
data are shown as mean ± SD. (G) CBFβ protein levels in control and 
knockdown cells were analyzed by immunoblotting.	 (*p<0.05, **p<0.005, 
***p<0.0005, One-way ANOVA multiple comparisons test) 
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Figure 2.6. Treatment with a RUNX-CBFβ inhibitor impairs the growth of 
human T-ALL cell lines and primary pediatric T-ALL samples. (A) Structures 
of inactive (AI-4-88) and active (AI-10-104) inhibitors. (B) The human T-ALL cell 
line Jurkat was treated with vehicle, 10μM of the inactive analogue AI-4-88, or 
with increasing concentrations of AI-10-104 for 4 days. Cells were stained with 
Annexin V-FITC and 7AAD and analyzed by flow cytometry. A representative 
flow profile of 3 independent experiments is shown. (C) Eight human T-ALL cell 
lines were treated with increasing concentrations of AI-10-104 for 3 days and cell 
growth/metabolism was analyzed by an MTS assay. (D) Human T-ALL cell lines 
and T-ALL patient samples were treated with increasing concentrations of the 
inactive analogue AI-4-88 (1-20μM) for 3 days. Cell growth/metabolism were 
analyzed by an MTS assay. (E) Eleven pediatric T-ALL patient samples were 
treated with vehicle or increasing concentrations of AI-10-104 (1-15μM) for 3 
days and cell growth/metabolism was analyzed by a CellTiterGlo assay. 
Absorbance values were normalized to those obtained with vehicle control. (F) 
Sensitivity of patient samples to AI-10-104 (GI50) correlates with RUNX1 and 
RUNX3 expression levels (Pearson’s r=0.8781, p=0.0093, sample TALL-X-5 
excluded). (G) Patient sample TALL-X-15 was treated with 10μM of AI-4-88 or 
with 5 or 10 μM of AI-10-104 for 6 days. Cells were stained with Annexin V-FITC 
and 7AAD and analyzed by flow cytometry. (H) Randomly selected patient 
samples (n=3) were treated with 10μM of AI-4-88 or 5, 10μM of AI-10-104 for 6 
days. Apoptotic cells were determined by Annexin V-FITC and 7AAD staining 
followed by flow cytometry. Three independent replicates are shown as mean ± 
SEM (*p<0.05, ***p<0.0005, ANOVA multiple comparisons test). 
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Figure 2.7. RUNX1/3-CBFb inhibitor is not detrimental to normal human 
hematopoietic stem and progenitor cells at low concentration. G-CSF 
mobilized normal human BM cells were treated with increasing concentrations of 
AI-10-104 for 3 days and effects on cell growth/metabolism were determined by 
MTS assay. The GI50 of each donor cell sample was calculated using Graph Pad 
Prism 7 software. 
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Figure 2.8. Reduction of RUNX1 expression in TLX3-transformed T-ALL cell 
line induces cell apoptosis. (A) The human T-ALL cell line HPB-ALL was 
transduced with lentiviruses expressing shRNAs against GFP or RUNX1. Gene 
expression in control or RUNX1 knockdown cells was determined by qRT-PCR. 
Three independent experiments were performed, and data are shown as mean 
with error bars representing ± SEM. (B) Apoptotic cells were quantified by 
Annexin V/7AAD staining followed by flow cytometry. Data are shown as the 
mean of 3 independent experiments with error bars representing ±SEM 
(**p<0.005, ***p<0.0005). 
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Table 2.1. Expression and mutation status in patient samples and human 
T-ALL cell lines. 
 
  
Patient samples
TALL-X-1 WT Yes No WT WT
TALL-X-2 WT Yes Yes p.P2514fs, 
p.F1592S
WT
TALL-X-3 WT Yes Yes p.L1593fs WT
TALL-X-4 WT Yes Yes p.F1592S WT
TALL-X-5 WT Yes Yes p.L1585P WT
TALL-X-7 WT Yes Yes p.L1600P p.R479Q
TALL-X-9 WT No Yes p.R1598P WT
TALL-X-13 WT Yes Yes WT WT
TALL-X-14 WT No No WT p.R465H
TALL-X-15 WT Yes Yes WT WT
Human cell lines
Jurkat p.A122T WT
KOPTK1 N/A N/A
MOLT4 WT WT
PF382 WT WT
HPB-ALL WT WT
TALL-1 WT WT
LOUCY WT WT
RUNX3 mutation status in patient samples is not available. 
As determined by western blot analysis. 
N/A, Not available
DND41 WT WT WTp.L1593P, p.D1609V,p.V2444fs*35
RPMI8402 WT WT p.R465Hp.E1583_Q1584insPVELMPPE, p.Q1584>HRGADAAGA
WT
WT
NOTCH1
WT
p.L1600P, p.P2515fs
p.L1574P, p.P2493fs*>67
WT
WT
p.L1574P, p.D2443fs*39
p.L1600P, p.P2514fs*4
p.R465H, p.D527G
FBW7
p.R505C
WT
WT
WT
Supplementary Table 1. Expression and mutation status in patient samples and human T-ALL 
cell lines.
p.T450fs, 
p.R689WTALL-X-8 Yes
FBW7
p.R1598P
NOTCH1
RUNX1 RUNX3
TAL1 
detected
NICD 
detected
RUNX1
WT Yes
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Table 2.2. Human T-ALL cell lines and primary patient samples are 
sensitive to AI-10-104 treatment. 
 
  
 GI50 ± SEM(µM)
Cell Line
Jurkat 8.2 ± 0.4 
KOTPK1 5.9 ± 0.5 
PRMI8402 4.3 ± 0.4 
MOLT4 5.7 ± 0.3
PF382 5.8 ± 0.3 
HPB-ALL 6.6 ± 0.5 
DND-41 5.2 ± 0.5 
TALL-1 7.0 ± 0.5
LOUCY* 11.0 ± 1.1
Average 6.1
Patient sample
Diagnostic
TALL-X-1 0.9 ± 0.1 
TALL-X-2 2.8 ± 0.6
TALL-X-3 1.1 ± 0.1 
TALL-X-4 4.3 ± 6.2 
TALL-X-5 4.4 ± 1.0
TALL-X-7 0.7 ± 0.1 
TALL-X-8 2.7 ± 0.8
TALL-X-9 0.9 ± 0.1 
Relapsed
TALL-X-13 1.3 ± 0.1 
TALL-X-14 3.0 ± 0.5 
TALL-X-15 4.3 ± 0.8
Average 2.4
*GI50 of LOUCY cell line is excluded from the average of GI50.
GI50 values of the inhibitor are shown for each cell line and patient 
sample analyzed 2 or 3 times.
Supplementary Table 2. Human T-ALL cell lines and primary 
patient samples are sensitive to AI-10-104 treatment.
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Table 2.3. shRNA clones used in the study 
 
  
Supplementary Table 4. shRNA clones used in the study
shRNA clone Clone ID Target gene
shRUNX1 #1 TRCN0000013659 RUNX1
shRUNX1 #2 TRCN0000013660 RUNX1
shRUNX3 #1 TRCN0000235675 RUNX3
shRUNX3 #2 TRCN0000235674 RUNX3
shCBFb #1 TRCN0000016644 CBFb 
shCBFb #2 TRCN0000016645 CBFb 
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Chapter III 
RUNX1 supports T-ALL survival by 
regulating Myb and Myc enhancer activity  
 
 
 
 
 
 
 
 
Data from the following chapter are a part of a published paper:  
AHyun Choi, Anuradha Illendula, John A. Pulikkan, Justine E. Roderick, Jessica Tesell, 
Jun Yu, Nicole Hermance, Lihua Julie Zhu, Lucio H. Castilla, John H. Bushweller and 
Michelle A. Kelliher. RUNX1 is required for oncogenic Myb and Myc enhancer activity in 
T cell acute lymphoblastic Blood (2017) 12;130(15):1722-1733 
 
The manuscript has been edited for this thesis to show the results generated by AHyun 
Choi. Data generated by others are noted.   
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Introduction 
Transcriptional regulation is a process of interplay of transcription factors, 
cofactors, other chromatin regulators, and core components of basal 
transcriptional machinery that bind to regulatory elements such as promoters, 
enhancers, and silencers of genes. It has been suggested that multiple 
transcription factors bind cooperatively to individual enhancer loci and recruit 
cofactors with polymerase II to target genes for expression regulation (370–372).  
RUNX1, a critical transcription factor for hematopoiesis and lymphoid 
lineage development, was observed to bind mostly to intergenic or intragenic 
regions in mouse hematopoietic stem and progenitor cells (373). In T-ALL cells, 
RUNX1 shares its binding sites with TAL1 and NOTCH1 (237,325). TAL1 binds 
to its target loci as an interconnected transcriptional regulatory complex and most 
of TAL1 binding sites in T-ALL cells are mapped to intergenic or intragenic 
regions where enhancer elements are located (93,237). ChIP-seq studies for 
NOTCH1 in T-ALL demonstrated that the majority of dynamic NOTCH1 binding 
sites that are sensitive to inhibition of NOTCH1 signaling are mainly located at 
distal sites rather than at promoter regions of target genes (324). Therefore, it 
appears that in T-ALL RUNX1 binds to enhancer regions along with TAL1 and 
NOTCH1 in order to regulate critical genes for T-ALL pathogenesis. 
In Chapter III, we demonstrate that Runx1 deletion in mouse T-ALL cells 
interferes with Myb and Myc enhancer activity resulting in decreases in gene 
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expression. Similarly, we observed that not only RUNX1, but also RUNX3 binds 
to MYB and MYC enhancer regions in the KOPTK1 human T-ALL cell line. 
Furthermore, we demonstrate that RUNX1 may be important for the maintenance 
of chromatin loop formation between promoter and enhancer elements of the 
MYB gene.   
Results 
RUNX1 supports the expression of a subset of TAL1- and NOTCH1-
regulated genes 
We hypothesized that Runx1 deletion, although unlikely to influence 
transgenic Tal1 mRNA levels, may suppress TAL1/LMO2-regulated genes 
important in mouse thymocyte survival, proliferation, and differentiation. RUNX1 
regulates genes important in thymocyte development and represses CD4 
expression during the DP to SP thymocyte transition (62). In addition to 
significant decreases in the RUNX1-regulated genes Cxcr4 and Bcl2, we 
observed increases in Cd4 and Cdkn1a mRNA expression in Runx1-deleted 
mouse T-ALLs (Figure 3.1A). Similarly, RUNX1 suppression in mouse and 
human T-ALL cell lines resulted in a partial derepression of the CD4 co-receptor, 
resulting in statistically significant increases in the mean fluorescent intensity of 
cell surface CD4 staining in RUNX1-deficient T-ALL cells (Figure 3.3). These 
data suggest that in mouse and human T-ALL cells, RUNX1 depletion may 
stimulate leukemic cell differentiation prior to induction of apoptosis.  
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Significant reductions in Myb, Gata3 and Cdk6 expression were also 
observed in Runx1-deleted mouse T-ALL cells and in the human TAL1-positive 
T-ALL cell line Jurkat (Figure 3.1A, 3.2). These data reveal that the TAL1-
RUNX1-GATA3 autoregulatory loop is conserved in this mouse T-ALL model 
driven by the TAL1 oncogene. Moreover, we demonstrate that TAL1/LMO2-
mediated mouse leukemic growth requires MYB in vitro and in vivo (367).  
Using a RUNX1-regulated gene set and genes induced upon NOTCH1 
reactivation (237,374), we performed Gene Set Enrichment Analysis (GSEA) and 
identified a subset of NOTCH1-regulated genes that were also affected by 
RUNX1 knockdown in human T-ALL cells (Figure 3.1B; NES=1.49; FDR=0.026). 
We observed significant reductions in the expression of Notch1, Myc, Il7rα, Igf1r, 
and Deltex1 mRNAs in the Runx1-deleted mouse T-ALL cell line (Figure 3.1C). 
This is the first report demonstrating that RUNX1 regulates NOTCH1 expression 
in mouse T-ALL cells. Runx1 deletion had no effect however, on Hes1 mRNA 
levels or on intracellular NOTCH1 binding to the mouse Hes1 promoter (Figure 
3.1C). Similarly, no significant change in human HES1 expression was observed 
upon RUNX1 knockdown in Jurkat cells (Figure 3.2A), indicating that a subset of 
NOTCH1-regulated genes is RUNX1-dependent. RUNX1 depletion in human T-
ALL cell lines consistently decreased the expression of MYC and IL7Rα. These 
data are consistent with published chromatin immunoprecipitation sequencing 
(ChIP-seq) studies demonstrating that RUNX1 co-occupies a subset of 
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NOTCH1-regulated genes and prior demonstration that RUNX1 and NOTCH1 
regulate IL7R expression (324). 
 We demonstrated that the pro-survival role of RUNX1 extends to the 
TAL1-negative, TLX3-transformed HPB-ALL T-ALL cell line (Figure 2.8). We 
hypothesized that RUNX1 supports survival of HPB-ALL cells by interaction with 
NOTCH1 signaling, which is aberrantly activated due to the mutations in HPB-
ALL (Table 1, (167)). We validated that the expression of NOTCH1-regulated 
genes that were dependent on RUNX1 in TAL1-positive T-ALL cells were altered 
in HPB-ALL cells by RUNX1 knockdown as well; the expression of MYC, IL7R 
and IGF1R were significantly reduced (Figure 3.2). Reductions in MYB 
expression were also observed (Figure 3.2), suggesting that RUNX1 may 
regulate MYB expression in the absence of TAL1. 
 Although the features that predict a RUNX1 dependency remain unclear, 
several of the TAL1- and NOTCH1-regulated genes supported by RUNX1 are 
associated with super-enhancers in human T-ALL cells (340), suggesting that 
enhancer-regulated genes may be uniquely sensitive to the effects of RUNX1 
depletion. 
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RUNX1 is required for TAL1 and NOTCH1 binding and recruitment of active 
histone mark to oncogene enhancers 
Comparisons between the mouse and human MYB genes reveal the 
presence of conserved locus-control-like regions (LCLR) located 
approximately -92-kb and +15-kb from the mouse Myb promoter and -93-kb and 
+14-kb from human MYB promoter (Figure 3.4B, (237,260)). These sites possess 
several features associated with enhancer activity, including the presence of 
multiple transcription factors (TAL1, RUNX1, HEB, GATA3 and ETS1), as well as 
RNA polymerase II, Mediator, BRD4 and acetylated H3K27 (237,340,364). The 
mouse Myb (-92-kb and +15-kb) regions each harbor one canonical RUNX 
binding site and RUNX1 binding to these conserved regions is observed in 
mouse T-ALL cells (Figure 3.4B-D). To determine if Runx1 deletion in mouse T-
ALL cells affects TAL1 binding to these regions, we performed chromatin 
immunoprecipitation followed by real time quantitative PCR (ChIP-qPCR). We 
observed statistically significant reductions in TAL1 binding to the Myb +15-kb 
and -92-kb enhancer elements (Figure 3.4C,D) and decreases in Myb mRNA 
levels (Figure 3.1A) in the Runx1-deleted T-ALL cells. Reductions in TAL1 
occupancy were accompanied by significant depletion of the active chromatin 
mark H3K27ac at these sites (Figure 3.4C, D). 
NOTCH1 contributes to T-ALL growth via its direct regulation of MYC 
(179–181). NOTCH1 regulation of MYC is mediated through a distal enhancer 
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located 1.27 Mb 3’ from the transcriptional start site (TSS) of the mouse Myc 
gene and 1.4 Mb from the TSS of the human MYC gene (208,351). This region 
was designated the NOTCH1-bound MYC enhancer (N-Me) and shown to be 
essential for NOTCH1-mediated MYC expression during mouse thymocyte 
development and for NOTCH1-mediated leukemic transformation (351). We 
examined intracellular NOTCH1 binding to the N-Me in the Runx1-deleted mouse 
TAL1/LMO2 T-ALL cells. Consistent with the observed reductions in Myc mRNA 
(Figure 3.1C), intracellular NOTCH1 binding at the N-Me and H3K27ac levels 
were significantly reduced in the Runx1-deficient mouse T-ALL cells (Figure 
3.5C), whereas no differences in TAL1 or intracellular NOTCH1 binding to gene 
desert regions were observed (Figure 3.6B). We also found the Histone 3 (H3) 
levels increased at the enhancer regions examined (Figures 3.4D and 3.5C), 
suggesting that Runx1 deletion results in increased H3 loading and a closed 
chromatin configuration. We used an assay for transposase accessible chromatin 
(ATAC) and observed decreased ATAC-qPCR enrichment at the N-Me in Runx1-
deleted leukemic cells (Figure 3.5D). These data suggest that a RUNX1 
deficiency results in transcription factor depletion and reduced chromatin 
accessibility at the N-Me. In addition, treatment of mutant NOTCH1 human T-ALL 
cells with the RUNX inhibitor resulted in statistically significant reductions in MYC 
mRNA levels, suggesting that AI-10-104 interferes with NOTCH1/MYC enhancer 
activity (Figure 3.5E). 
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In addition to RUNX1, we detected RUNX3 expression in a subset of 
human T-ALL cell lines and primary patient samples (Figure 2.4) and induced 
apoptosis upon RUNX1 or RUNX3 knockdown in KOPTK1 (Figure 2.5D,E), 
indicating that both RUNX1 and RUNX3 support the survival of these human T-
ALL cells. Consistent with these data, we detected RUNX1 and RUNX3 binding 
at the N-Me and found MYC expression significantly reduced in the RUNX1- or 
RUNX3-suppressed KOPTK1 cells (Figure 3.7A,C,D). Although we detected 
RUNX1 and RUNX3 binding at the MYB -93-kb enhancer, neither protein was 
detected at the +14-kb enhancer, (Figure 3.7A). Suppression of RUNX1 or 
RUNX3 reduced MYB expression however, statistical significance was achieved 
only in the RUNX1-silenced cells (Figure 3.7C,D). Unlike RUNX1, RUNX3 
suppression in Jurkat cells did not induce apoptosis (Figure 2.5D,E) nor was 
RUNX3 binding detected at the MYC or MYB enhancer elements bound by 
RUNX1 (Figure 3.7B). These data reveal that KOPTK1 cells rely on RUNX1 and 
RUNX3 to maintain MYC and MYB levels, whereas in Jurkat cells, RUNX1 
supports MYC and MYB expression and RUNX3 does not contribute. Our 
findings suggest that the relative levels of RUNX1 and RUNX3 may dictate their 
roles in MYC and MYB regulation and that TALL survival requires a certain 
threshold level of CBFβ/RUNX1 and/or RUNX3. Interestingly, we did not observe 
increased expression of RUNX3 upon RUNX1 knockdown and vice versa 
(Figure 3.8).  
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RUNX1 regulates chromatin structure around the MYB gene. 
 It has been demonstrated that enhancer elements located at distal sites 
regulate the expression of associated genes by physical interactions involving 
chromatin looping between the enhancer and promoter regions (370,375–377). 
Transcription factors and cofactors that bind to the enhancer regions have been 
shown to play key roles in the formation and maintenance of looping structures 
(378,379). To investigate whether there are chromatin loops between promoter 
and enhancer regions, we examined whether RUNX1 is required for the 
formation, we performed chromatin conformation capture (3C) analysis around 
the MYB gene in the Jurkat human T-ALL cell line with or without RUNX1 
suppression by doxycycline- induced RUNX1-shRNA expression (Figure 3.9A). 
3C analysis demonstrated that the MYB +14-kb or -93-kb enhancer region was 
placed in close proximity to the promoter region of MYB gene which was 
released by RUNX1 suppression (Figure 3.9B), consistent with reduced MYB 
expression (Figure 3.9A). These data suggest that RUNX1 regulates MYB 
expression by controlling the activity of enhancer regions and by engaging in 
chromatin structure formation between the enhancer and promoter elements.  
Discussion 
We show that a RUNX1 deficiency reduces transcription factor binding at 
the mouse Myb +15-kb and -92-kb enhancers and the NOTCH1 bound Myc-
enhancer (N-Me). The reductions in TAL1 binding to the mouse Myb enhancer 
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regions in Runx1-deleted T-ALL cells are particularly noteworthy as the proximal 
Lck promoter drives Tal1 expression and consequently, reductions in TAL1 
binding at the Myb enhancer do not reflect RUNX1 effects on endogenous Tal1 
transcription. These data suggest that in addition to regulating TAL1 expression 
(237), RUNX1 supports TAL1 binding to the Myb enhancer. We also find that 
Cdk6 expression depends on RUNX1 (Figure 3.1A), and consistent with our data, 
Palii et al.(93) showed that RUNX1/3 suppression in Jurkat cells reduced TAL1 
binding to several genes important in thymocyte differentiation, including the 
CDK6 locus. In this study however, RUNX1/3 knockdown had no detectable 
effect on TAL1 expression, suggesting that RUNX1 primarily regulates TAL1 
binding. These findings are relevant to T-ALL patients, as most patients activate 
TAL1 expression via chromosomal rearrangements that displace the TAL1 
promoter and thereby subvert RUNX1-mediated effects on TAL1 transcription. 
Precisely how a RUNX1 deficiency interferes with TAL1 and intracellular 
NOTCH1 binding to these enhancer regions, respectively is unclear. RUNX1 has 
been shown to interact with TAL1 and intracellular NOTCH1 in T-ALL cells 
(93,380), suggesting that RUNX1 may be a component of both transcriptional 
complexes. However, the E-box, RUNX, and NOTCH1/CSL/RBJκ consensus 
sites are dispersed throughout the conserved Myb and Myc enhancer regions 
examined, making it unlikely that TAL1/RUNX1 or intracellular NOTCH1/RUNX1 
bind as single complexes. 
	 
86 
A RUNX1 deficiency results in decreases in the active chromatin mark 
H3K27ac and increases in H3 loading (Figures 3.4, 3.5), raising the possibility 
that RUNX1 directly regulates chromatin, recruits histone modifying enzymes, 
and/or other chromatin regulators to these enhancer regions. RUNX1 has been 
shown to interact with histone acetyltransferase p300 (39) and BRG (43), the 
ATPase subunit of SWI/SNF chromatin remodeling complex. BRG1 knockdown 
led to marked reductions in transcription factor binding and disruption of the MYC 
1.7-Mb enhancer:promoter interaction in AML cells (352). Similarly, NOTCH1 
inhibition interferes with N-Me interactions with the MYC promoter and 
suppresses MYC mRNA levels (208). Our data show that a RUNX1 deficiency 
evicts TAL1 and NOTCH1 from the Myb and Myc enhancers respectively, and 
that reduction of RUNX1 expression dissociated the interaction between the +14-
kb or -93-kb enhancer and the MYB promoter. Therefore, we speculate that 
RUNX1 depletion destabilizes N-Me and the promoter interaction, and that 
RUNX1 plays a key role in chromatin structure formation. 
Attempts have been made to target enhancers in cancer therapy using 
BET bromodomain inhibitors or histone modifying enzymes. The obvious concern 
is that such treatments would have toxic side effects due to inhibition of enhancer 
activity in normal cells. Although the BRD4 inhibitor JQ1 has clear anti-leukemic 
activity via its effects on MYC (205,207,381), toxicities have been observed and 
RNAi-mediated inhibition of BRD4 in mice has deleterious effects on tissue 
homeostasis (382). These findings predict that targeting broad regulators of 
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enhancer activity may interfere with normal tissue repair and regeneration and 
may not be tolerated long term in patients. 
Our genetic and pharmacologic experiments reveal that targeting RUNX1 
might be an alternative strategy to disrupt oncogenic MYB and MYC enhancers 
in T-ALL and elicit anti-leukemia activity. With the development of more potent 
and stable AI-10-104 analogues, the effects of RUNX1 inhibition can be tested in 
preclinical mouse and human T-ALL models for efficacy and to ensure the safety 
of the therapeutic strategy. 
Materials and Methods 
RNA analyses. RNA isolation and qRT-PCR were performed as described in 
Chapter II.   
ChIP-qPCR. Chromatin immunoprecipitation was performed as previously 
described (383). Mouse T-ALL cells treated with ethanol or 10nM 4-OHT were 
lysed and nuclei were fragmented into 150~300-bp size pieces using Bioruptor 
(Diagenode). Fragmented chromatin was incubated overnight at 4°C with normal 
IgG (sc-2027, Santa Cruz) or anti-TAL1 (C-21, Santa Cruz), anti-RUNX1 
(ab23980, Abcam), anti-RUNX3 (9647, cell signaling), anti-NOTCH1 (C-20, 
Santa Cruz), anti-Histone 3 (ab1791, Abcam) or anti-H2K27ac (ab4729, Abcam). 
Chromatin antibody complexes were pulled down by incubating with magnetic 
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beads (Dynal) for 4 hours. Enrichment of DNA fragments was tested using qPCR 
with primers specific for sites of interest (Table 4). 
ATAC-qPCR Assay for transposase-accessible chromatin with quantitative PCR 
experiment was performed as previously described (384) with minor modification 
to reduce mitochondria DNA contamination. Briefly, mouse T-ALL cells (1x106) 
treated with EtOH or 10nM of 4-OHT for 48 hours were harvested and lysed 
using a dounce homogenizer in 25 mM Tris pH 8.0, 2 mM MgCl2 buffer. Nuclei 
were pelleted by centrifugation at 500 g, 4°C for 10 minutes and washed with 
cold PBS twice. Nuclei were resuspended with 50 µl of cold lysis buffer (10 mM 
Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% (v/v) Igepal CA-630) and 
tagmented as described before (384). To enrich DNA fragments of nucleosome-
free and mononucleosome-occupied regions, final PCR products were selected 
using a negative Solid Phase Reversible Immobilization (SPRI)-size selection of 
0.6x followed by a positive SPRI-size selection of 1.4x. Size-selected DNA from 3 
biological replicates of each condition were amplified using qPCR with primers 
specific for the sites of interest (Table 5) to examine the enrichment of DNA 
fragments. The degree of accessibility to the N-Me region was normalized as fold 
of enrichment over the degree of accessibility to 2 distinct gene desert regions.  
Doxycycline-inducible RUNX1-shRNA Jurkat clone A Jurkat clone expressing 
shRNA against RUNX1 upon doxycycline treatment was a generous gift from Dr. 
Marjorie Brand at the Sprott Center for Stem Cell Research, Canada. Cells were 
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treated with 5 µg/ml of doxycycline for 48 hours in order to suppress RUNX1 
expression.  
3C 5x10^6 of RUNX1-shRNA expressing Jurkat cells were collected and 
crosslinked using formaldehyde. A 3C library was generated as previously 
described (385).     
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Figure 3.1. RUNX1 regulates a subset of TAL1-, and NOTCH1-regulated 
genes. (A) mRNA was isolated from mouse T-ALL cells 48 hours after vehicle or 
4-OHT treatment and the expression of subset of a RUNX1- and TAL1- regulated 
genes was determined by qRT-PCR. Three to 4 independent experiments were 
performed, and data are shown as mean ± SEM. (B) Gene Set Enrichment 
Analysis (GSEA) of RUNX1-regulated genes and genes changed upon 
reactivation of NOTCH1 by GSI washout (325). RUNX1 target genes that were 
significantly downregulated by RUNX1 knockdown in Jurkat cells were used as a 
data set (237). (C) The expression of a subset of NOTCH1-regulated genes in 
Runx1-deleted mouse T-ALL cells was determined by qRT-PCR. Three to 
4 independent experiments were performed, and data are shown as mean ± 
SEM (*p<0.05, **p<0.005, ***p<0.0005, Student t test). (GSEA assay [panel B] 
was performed by Jun Yu) 
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Figure 3.2. RUNX1 knockdown in human T-ALL cell lines alters the 
expression of a subset of RUNX1-, TAL1-, and NOTCH1-regulated genes. (A) 
Jurkat cells were infected with lentiviruses expressing shRNA against RUNX1 or 
GFP. RNA was isolated 4 days after infection. The expression changes of a 
subset of RUNX1-, TAL1-, NOTCH1-regulated gene upon RUNX1 knockdown 
were determined by qRT-PCR. (B) The expression of subset of NOTCH1-
regulated genes were altered by RUNX1 reduction.  GAPDH was used for 
normalization of qPCR values. Three to 4 independent experiments were 
performed, and data are shown as mean ± SEM (*p<0.05, **p<0.005, 
***p<0.0005, ****p<0.0001, One-way ANOVA multiple comparisons test).   
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Figure 3.3. RUNX1 depletion derepresses CD4 cell surface expression on T-
ALL cells. (A) CD4 cell surface expression in RUNX1-silenced Jurkat human T-
ALL cells was determined by flow cytometry after staining with CD4 antibody. 
Representative flow data is shown and data from 3 independent experiments are 
shown as MFI ± SD (right). (B) CD4 and CD8 expression in mouse T-ALL cells 
were determined by flow cytometry. Mouse T-ALL cells were stained with CD4-
PerCP-Cy5.5 and CD8-FITC antibodies 48 hours after EtOH or 5, 10 nM of 4-
OTH treatment.	 One representative flow profile is shown (left). The mean of 
fluorescence of CD4-PerCP-Cy5.5 from 3 independent experiments is shown as 
MFI ± SEM (right) (*p<0.05, ***<p0.0005, **** p<0.0001, One-way ANOVA 
multiple comparison). Panel B data were presented for reviewers only.  
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Figure 3.4. RUNX1 is required for TAL1 binding to the Myb enhancers and 
for the retention of active chromatin marks. (A) H3K27ac, TAL1, and RUNX1 
enrichment at the MYB locus by ChIP-Seq are shown in genome browser tracks 
(genome.ucsc.edu/human hg19). (B) Mouse genomic region (mm10) around Myb 
locus, depicting the E-BOX (TAL1) and RUNX binding sites at positions +15 kb 
and -92 kb from the Myb TSS. (C, D) Enrichment of RUNX1, TAL1, H3K27ac, 
and histone 3 to +15 kb (C) and -92 kb (D) Myb enhancer regions determined by 
ChIP-qPCR in control or Runx1-deleted mouse T-ALL cells. Data are shown as 
the mean of 3 or 4 independent experiments with error bars representing ± SEM 
(*p<0.05, *p<0.005, p<0.0005, Two-way ANOVA multiple comparisons test). 
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Figure 3.5. RUNX1 is required for intracellular NOTCH1 binding and for 
chromatin accessibility at the N-Me. (A) H3K27ac, NOTCH1, and RUNX1 
enrichment at human MYC super-enhancer are shown in genome browser tracks 
(genome.ucsc.edu/human hg19). (B) Mouse genomic region (mm10) 
encompassing Myc and its enhancer loci located 1.27 Mb from the TSS. The 
RBPJ and RUNX binding sites are depicted. (C) Recruitment of RUNX1, 
intracellular NOTCH1, H3K27ac and histone 3 to mouse Myc enhancer was 
determined by ChIP-qPCR in control or Runx1-deleted mouse T-ALLs. (D) The 
degree of open chromatin at N-Me enhancer region in control or Runx1-deleted 
mouse T-ALLs was determined by ATAC-qPCR. (E) MYC gene expression 
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changes were determined in RPMI8402 cells treated with 10 μM of AI-4-88 or AI-
10-104 for 12 hours. Data shown are the mean of 3 or 4 independent 
experiments and error bars represent ± SEM (*p<0.05, **p<0.005, ***p<0.0005, 
Two-way ANOVA multiple comparisons test for ChIP-qPCR, Student t test for 
ATAC-qPCR and qRT-PCR). 
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Figure 3.6. Runx1 depletion has no effect on intracellular NOTCH1 binding 
to the Hes1 promoter or to gene desert regions. (A) Runx1 deletion did not 
change the recruitment of intracellular NOTCH1 or H3K27ac to the mouse Hes1 
promoter. (B) Runx1 deletion has no effect on TAL1, NOTCH1, or H3K27ac 
binding to gene desert region. Two to 4 independent experiments were 
performed and data are shown as mean ± SEM. 
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Figure 3.7. RUNX1/3 binding to the oncogenic enhancers reflects their 
regulation of gene expression. (A, B) RUNX1 and RUNX3 binding to N-Me, 
MYB+14 kb, and MYB-93 kb enhancer loci was determined by ChIP-qPCR in (A) 
KOPTK1 or (B) Jurkat cell lines. Data are shown as the mean of 4 independent 
experiments with error bars representing ± SEM (*p<0.05, Multiple t test). (C, D) 
The expression of MYB and MYC in (C) RUNX1-  or (D) RUNX3-silenced 
KOPTK1 cells were determined by qRT-PCR. Data are shown as mean of 3 or 
4 independent experiments with error bars representing ± SEM (*p<0.05, 
**p<0.005, ***p<0.0005, One-way ANOVA multiple comparisons test). 
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Figure 3.8. The reduced expression of RUNX1 or RUNX3 does not lead to 
increased expression of the other. The mRNA expression level of RUNX3 and 
RUNX1 upon knockdown of RUNX1 and RUNX3, respectively, was tested by 
qRT-PCR. Three to 4 biological replicates were collated.    
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Figure 3.9. RUNX1 reduction interferes with the formation of loop between 
the MYB promoter and -94-kb and +14-kb enhancers. (A) The expression of 
RUNX1 and MYB in Jurkat cells expressing inducible shRNA against RUNX1 
was determined by qRT-PCR after 48 hours of doxycycline treatment. (B) The 
Interaction between the MYB promoter region and downstream or upstream 
regions of the MYB TSS in Jurkat cells was analyzed by a 3C assay. Jurkat cells 
were treated with doxycycline for 48 hours to reduce RUNX1 expression. Data 
are shown as mean of 3 technical replicates with error bars representing ± SD 
(*p<0.05, **p<0.005, **p<0.0005). This result is unpublished data.  
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This thesis research has focused on investigating the roles of RUNX1 in 
T-ALL leukemogenesis. In contrast to the tumor suppressing functions of RUNX1 
in AML, I have demonstrated that RUNX1 is required for the survival and 
proliferation of human and mouse T-ALL cells. RUNX1 depletion reduces the 
expression of genes that are essential for T-ALL survival. Especially, RUNX1 
supports Myb and Myc expression by regulating transcription factor binding and 
acetylation of H3K27 at the Myb and Myc enhancers. In addition, RUNX1 
appears to change the chromatin structure around the MYB gene. Furthermore, I 
provided evidence that RUNX1 can be a therapeutic target in T-ALL by using a 
recently developed RUNX1/CBFb inhibitor. 
RUNX1 contributions to T-ALL cell leukemogenesis.  
 Previously, RUNX1 was proposed to be a tumor suppressor in T-ALL 
based on the findings of recurrent mutations in the RUNX1 gene in the early 
T-cell precursor acute lymphoblastic leukemia (ETP-ALL) subtype (131,321,323). 
The identified mutations have been shown to, or are predicted to, result in loss of 
function of RUNX1 (305,323), suggesting that disturbing RUNX1 role would lead 
to T-ALL leukemogenesis. In addition, Runx1 deficient mice treated with N-ethyl-
nitrosourea (ENU) predisposed to T-ALL development (369). However, I have 
demonstrated that RUNX1 depletion resulted in apoptosis in T-ALL cells, arguing 
a pro-survival function of RUNX1. In contrast to previous studies, all human T-
ALL cell lines and patient samples examined in this research are typical T-ALLs. 
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In addition, except the Jurkat cell line, they harbor wildtype RUNX1 (Table 1.1). 
Consistently, it has been reported that RUNX1 mutations are very rare in non-
ETP-ALL patients (131), indicating that RUNX1 has distinct functions depending 
on T-ALL subtypes. The immunophenotype and gene expression profile of ETP-
ALL cells suggests that ETP-ALL arises from ETP cells; they are recent 
immigrants from BM to thymus expressing one or more of myeloid or stem-cells 
markers, such as CD117, CD34, CD13, and CD13, but not lymphoid markers, 
such as CD8 and CDa1, and have both lymphoid and myeloid development 
potential (130,386). Thus, in ETP cells, loss-of-function RUNX1 mutations likely 
promotes leukemogenesis, similarly to how it does in myeloid lineage cells. On 
the other hand, during cortical T-ALL development, normal RUNX1 regulation 
seems to be sustained until the emergence of more mature DN3 thymocytes, the 
presumed target cell clones of cortical T-ALL (175,205). Deregulated TAL1 or 
NOTCH1 may prevent RUNX1 downregulation that normally occurs during DP to 
SP thymocyte differentiation (63). RUNX1 overexpression resulted in resistance 
to TCR-mediated apoptosis (387) while reduction of RUNX1 activity in DP cells 
sensitizes cells to apoptosis induced by TCR signaling (388). These studies 
indicate that RUNX1 plays a pro-survival role in the DN4 or DP late stage 
thymocyte developments. Consistently, the expression levels of RUNX1 in TAL1-
positive T-ALL patient samples is higher than in other T-ALL subtypes (237).  
 It was reported that Jurkat cells harbor a RUNX1 mutation within the 
RUNT domain, which could affect the DNA binding capability of RUNX1 (323). 
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However, ChIP-seq studies of RUNX1 in Jurkat cells displayed a significant level 
of DNA binding affinity (237,389). In addition, reduction of RUNX1 expression in 
this cell line induced apoptosis and altered the expression of known RUNX1 
target genes such as CD4 and CXCR4. Therefore, the RUNX1 mutation in Jurkat 
cells does not seem to result in loss of function of RUNX1.   
 Analyses of signal distribution of acetylated histone 3 lysine 27 (H3K27ac), 
which locates at active enhancer regions, have identified super-enhancers 
enriched with high- and broad-signals of H3K27ac, and their associated genes in 
Jurkat and PRMI8402 T-ALL cells lines (340,364). These studies reveal that the 
RUNX1 gene is expressed by a super-enhancer that contains the hematopoietic 
cell-specific enhancer at 23kb downstream from RUNX1 TSS in T-ALL cell lines 
(340,364,390). This is also supported by the finding that in T-ALL, expression of 
RUNX1 is exceptionally sensitive to a low dose of THZ1 (50nM), an inhibitor of 
CDK7 (an essential cofactor of transcriptional machinery), given that super-
enhancers are highly sensitive to disruption (347,364). These studies indicate 
that RUNX1 is a master transcription factor determining the identity of T-ALL 
cells. Consistently, I have demonstrated that RUNX1 depletion using RUNX1-
shRNA and AI-10-104 inhibitor resulted in cell death of multiple T-ALL cell lines 
and patient samples. 	
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RUNX1 regulates the activity of super-enhancers and chromatin structure 
in T-ALL. 
I have demonstrated that Runx1 deletion in murine T-ALL cells results in 
reduced modification of active histone mark, H3K27ac, to the Myb and Myc 
enhancer loci, which have been identified as super-enhancers (351,364). 
Consistently, the expression of MYB and MYC are downregulated following 
RUNX1 depletion in both human and mouse T-ALL cells, suggesting that RUNX1 
is involved in the activation of super-enhancer elements. It has been shown that 
RUNX1 can recruit histone acetyltransferases such as CBP/P300 and monocytic 
leukemia zinc finger protein (MOZ) to the DNA where it binds (39,391) and 
becomes capable of regulating histone acetylation. In addition to control of the 
recruitment of histone acetyltransferase to DNA, open chromatin regions in 
Runx1 deleted mouse T-ALL cells defined by ATAC-seq experiment suggest that 
RUNX1 may regulate expression of histone modification enzymes (Appendix II). 
The accessibility of promoter regions of genes involved in histone modification 
including Setd2 (Histone-lysine N-methyltransferase SETD2), Kmt5a (lysine 
methyltransferase 5A), Kat14 (lysine acetyltransferase 14), and Dot1l (DOT1 like 
histone lysine methyltransferase), is increased upon Runx1 deletion in mouse T-
ALL cells. However, the gene expression profile using a microarray assay in 
RUNX1-silenced human T-ALL cells did not reveal expression changes of these 
genes (237). This discrepancy might be caused by human versus mouse species 
difference or by lack of sensitivity of the array assay. Therefore, it needs to be 
	 
105 
tested whether RUNX1 depletion in mouse T-ALL cells alters the expression 
levels of these enzymes leading to changes in histone modifications using an 
RNA-seq experiment. Collectively, RUNX1 appears to be responsible for marking 
regulatory regions for the activation or repression and the recruitment of 
transcriptional machinery, regulating the expression of target genes.	 
Interestingly, I observed that RUNX1 depletion inhibited binding of 
transcription factors, TAL1 and NOTCH1 to the Myb and Myc super-enhancer 
loci, respectively, leading to disruption of TAL1-MYB and NOTCH1-MYC 
oncogenic pathways in mouse T-ALL cells. Given that RUNX1 shares a 
significant portion of its binding sites with members of the transcriptional complex 
in T-ALL (234,237,324) and NOTCH1, it is possible that RUNX1 regulates TAL1 
and NOTCH1 binding to other loci besides the MYB and MYC enhancers. 
Consistently, I observed that RUNX1 reduction resulted in downregulation of a 
subset of TAL1- and NOTCH1-target genes. Interestingly, these genes are also 
associated with super-enhancers that are bound by RUNX1 (324,364). Thus, 
RUNX1 inhibition will lead to disruption of TAL1 and NOTCH1 regulation by 
preventing them from binding to super-enhancers that drive expression of genes 
critical for defining the identity of T-ALL cells.  
How RUNX1 controls TAL1 and NOTCH1 binding to enhancer regions is 
not clear either. Although TAL1 and NOTCH1 have been shown to interact with 
RUNX1 in T-ALL (93,380), it is unlikely that they bind to their binding sites as 
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single complexes based on the distances between their consensus binding 
motifs in the MYB and MYC enhancer regions. Instead, it seems that they 
indirectly cooperate for their binding to target regions. It is possible that RUNX1 
acts as a ‘pioneer factor’ (372,392) that induces chromatin remodeling where it 
binds and repositions the nucleosome to expose binding motifs for other 
transcription factors, allowing their binding. RUNX1 has been shown to interact 
with the BRG1 SWI/SNF chromatin remodeling complex in T-ALL (43), although 
whether BRG1 recruitment to DNA is a cause or result of RUNX1 binding 
remains to be tested. Open promoter regions revealed by ATAC-seq in Runx1 
deleted mouse T-ALL cells are enriched with genes involved in chromosome 
organization such as Smarcb1 (SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily B member 1), Wdhd1 (WD repeat 
and HMG-box DNA binding protein 1), and Phf19 (PHD finger protein 19) 
(Appendix II). These data indicate that RUNX1 might regulate chromatin 
structure changes by controlling the expression of chromatin modifiers. In 
addition, MOZ, a coactivator interacting with RUNX1, has a motif that is 
responsible for nuclear localization and coactivation and is homologous to the 
H15 domain found in linker histones such as histone 1, and histone 5 (391). The 
H15 domain of histone 5 has been implicated in binding to the nucleosome (393), 
therefore, RUNX1 might bind to the compacted chromatin and induce chromatin 
structure changes through interaction with the MOZ coactivator. During the 
definitive hematopoiesis, it was shown that induced RUNX1 bound to distal 
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regulatory regions having low or absent active histone mark, H3K9ac, and 
subsequently increased the level of active histone mark. Furthermore, ChIP-seq 
for TAL1 demonstrated the increased number of TAL1 binding peaks next to the 
RUNX1 binding sites, indicating that RUNX1 binding to DNA provides new 
binding sites for TAL1 (394). To examine RUNX1 roles as a pioneer factor in 
T-ALL, binding of RUNX1 to silent chromatin, which does not contain histone 
modification, after RUNX1 induction in RUNX1-deficient cells can be tested using 
ChIP-seq for RUNX1. To prevent cell death caused by the RUNX1 deficiency, 
BCL-2 can be ectopically expressed. Change of histone modifications around 
RUNX1 bound regions will also demonstrate RUNX1 function as a pioneer factor. 
It can be validated by recruitment of other transcription factors, such as TAL1 
and NOTCH1, to the RUNX1 bound regions after the RUNX1 induction. 
On the other hand, RUNX1 can remain bound at its binding sites and 
prevent nucleosome repositioning, thus serving as a placeholder to let other 
transcription factors bind to adjacent sites. Consistently, I observed increased H3 
loading to the Myc enhancer region and global changes in the nucleosome 
position upon Runx1 deletion, indicating that RUNX1 may regulate nucleosome 
relocalization/positioning. Genome-wide changes of TAL1 or NOTCH1 binding 
after Runx1 deletion can be examined to verify the RUNX1 role as a placeholder 
in T-ALL cells.   
	 
108 
Whether TAL1 or NOTCH1 is required inversely for RUNX1 binding to 
these enhancer loci remains to be tested. In T-ALL cells overexpressing TAL1 by 
somatic mutations in TAL1 enhancer region, MYB binding appears to be critical 
for the binding of other transcription factors to the enhancer; the somatic 
mutations found in this newly generated super-enhancer region introduce only de 
novo MYB binding sites to the DNA resulting in binding of MYB and TAL1 
complex members, which does not occur in the wildtype allele that contains E-
Box, RUNX, ETS, and GATA3 but not MYB binding motifs (234). This study 
indicates that a specific transcription factor can determine binding of other 
transcription factors. In KOPTK1 cells, which express a minimal level of TAL1, I 
detected RUNX1 and RUNX3 binding to the -93-kb MYB enhancer locus. This 
result suggests that TAL1 may not be the determinant factor of RUNX1 binding to 
DNA. In addition, transgenic mice expressing Lmo2 and a DNA-binding mutant of 
Tal1 develop T-ALL indicating that TAL1 direct binding to DNA is not required for 
its regulation (87). Using CRISPR/CAS9-mediated genome editing to delete the 
binding sites of individual transcription factors in the enhancer region, we can 
examine the hierarchy of transcription factors binding to these regions. 
 Formation of looping structures connecting regulatory element regions has 
been proposed as a method of communication between long-range regulatory 
elements (351,395–397). 3C and 3C-based technologies have demonstrated that 
enhancers are placed in close physical proximity to the gene promoter regions to 
drive gene expression (181,352,377) and that RUNX1 mediates these 
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interactions (398–400). RUNX1 has been known to repress CD4 expression by 
binding to the silencer of the CD4 gene (62). 3C experiments have further shown 
that RUNX1 can induce the formation of chromatin loops between the enhancer 
and the silencer of the CD4 gene in DN thymocytes and a CD8ISP thymoma cell 
line. Consistent with this, RUNX1 silencing resulted in interaction between the 
enhancer and the promoter of CD4 gene, which induced the CD4 expression 
(398). RUNX1 regulation of the expression of CD34 in HSCs is also associated 
with chromatin loop formation connecting the enhancer and the promoter of the 
CD34 gene (399). In line with this, I demonstrated that RUNX1 suppression 
reduces the interaction frequency of the promoter with the enhancer regions of 
MYB gene and downregulates MYB, supporting a role for RUNX1 in local 
chromatin structure arrangement for transcriptional regulation. However, due to a 
difficulty to acquire sufficient suppression of RUNX1 in this inducible shRNA 
expressing system, inhibited DNA loop formation in RUNX1 depleted cells was 
not prominent. To confirm RUNX1 regulation of DNA looping, interaction 
frequency between the promoter and enhancer region can be examined in the 
RUNX1 binding site deleted cells using CRISPR/CAS9 system.  
It has been demonstrated that although the topologically associating 
domains (TADs), self-interacting domains, are conserved across different cell 
types, chromatin architectures within TAD are established in cell type-specific 
ways (401–403). Cell type-specific transcription factors and cofactors, such as 
mediator and cohesin, have been suggested to mediate the interaction between 
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regulatory regions within TAD (379,404). In Med1 (a component of mediator 
complex) or Smc1 (a component of cohesion complex) depleted embryonic stem 
cells (ESCs), the interactions of Nanog locus with other chromatin regions were 
disrupted which leading to decreased expression of Nanog and differentiation of 
ESCs (404). The binding sites of ESCs-specific transcription factors, including 
SOX2, KLF4, and ESRRB, are enriched at the interacting loci of Nanog 
suggesting roles of these transcription factors in the interaction of Naong locus 
with other regions (404). Therefore, it would be interesting to evaluate a role of 
RUNX1 in local chromatin organization around its other target genes besides 
MYB and throughout the genome in T-ALL cells in comparison to normal 
thymocytes. Genome-wide chromatin interaction in T-ALL cells in the presence 
or absence of RUNX1 can be tested by Hi-C (a genome-wide and unbiased 
method that combines 3C with deep sequencing) whether RUNX1 depletion 
rearranges chromatin interaction of T-ALL cells to a similar way of normal 
thymocytes.   
RUNX3 shares oncogenic roles of RUNX1 in T-ALL. 
 RUNX1 and RUNX3 are expressed differently during mouse thymocyte 
development in that RUNX1 is highly expressed in immature thymocytes while 
RUNX3 is expressed in mature CD8+ thymocytes (62,63). Consistently, I 
detected RUNX1 but not RUNX3 protein expression in our mouse T-ALL cells 
which resemble DP thymocytes. However, I also detected RUNX3 expression in 
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several human T-ALL cell lines and primary patient samples.  Although there is a 
report that RUNX3 is significantly downregulated in CD4ISP (CD4+CD8-CD3-) 
and DP (CD4+CD8+CD3-) human immature thymocytes (405), the expression 
pattern of RUNX1 and RUNX3 may be different in human T-cell development. 
For example, RUNX3 and RUNX1 may be expressed in immature human 
thymocytes. In addition, target cells of transformation could be more 
heterogeneous in human T-ALL compared to mouse T-ALL. 
In contrast with the large number of studies of RUNX1 in leukemogenesis, 
not much is known about RUNX3 in leukemia development. In other types of 
cancer, including colon and pancreatic cancer, RUNX3 has been suggested to 
function as either tumor suppressor or oncogene depending on tissue type 
(55,406–409). In this thesis, I have demonstrated that when co-expressed 
RUNX3 supports the survival of T-ALL cells similarly to RUNX1, indicating that 
RUNX1 and RUNX3 are functionally redundant. In addition, sensitivity to the 
RUNX inhibitor AI-10-104 correlates with the combined RUNX1 and RUNX3 
expression levels in patient samples (Figure 2.6F). I showed that RUNX3 
regulates MYB and MYC expression by binding to the MYB and MYC enhancer 
regions in KOPTK1 cells where RUNX1 binds, in accordance with the idea that 
they share DNA binding sites due to the highly-conserved RUNT domain. This is 
also in line with the finding that both RUNX1 and RUNX3 bind to the Cd8 
enhancer and FOXP3 (forkhead box P3) promoter regions in CD8SP cells and in 
naïve CD4+ T-cells, respectively (63,410). However, RUNX 1/3 do not appear to 
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functionally compensate for one another; depletion of RUNX1 or RUNX3 induces 
apoptosis. It is possible that a certain amount of time is required to see the 
compensatory effects. It has been shown that RUNX1 downregulation in AML 
results in alteration of RUNX1 target gene expression at early time points, that 
were not evident at later time points, with the increased expression of RUNX2 
and RUNX3 (411). The kinetics of RUNX1 and RUNX3 functions in T-ALL can be 
examined using inducible expression of shRNAs against RUNX1 and RUNX3. 
The target gene expression also can be tested in both RUNX1 and RUNX3 
depleted cells to confirm functional redundancy of RUNX1 and RUNX3. Its 
possible that the total amount of RUNX proteins might be critical for their function 
and T-ALL survival. The presence of RUNX binding motifs in regulatory regions 
of RUNX1 and RUNX3 indicate that RUNX1 and RUNX3 are likely to regulate 
each other, as seen in AML cells (411). However, I do not detect significant 
changes in RUNX1 expression upon RUNX3 knockdown, or vice versa, in 
KOPTK1 cells. In T-cells, a distinct regulatory mechanism seems to govern the 
expression of RUNX1 and RUNX3. In CD4+ native T-cells, both RUNX1 and 
RUNX3 regulate FOXP3 expression by binding to the promoter of the FOXP3 
gene. (410). During regulatory T (Treg)-cells development from human CD4+ 
naïve T-cells, RUNX3 expression was preferentially upregulated whereas 
RUNX1 expression was not changed. In addition, silencing of individual RUNX1 
and RUNX3 using siRNA did not induce the alteration of each other’s expression 
(410), suggesting that RUNX1 and RUNX3 do not regulate each other’s 
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expression in T-cells. During hematopoietic development, RUNX1 expression is 
regulated by a hematopoietic-specific enhancer located at 23kb downstream 
from the TSS (390) which is bound by TAL1, GATA2, and PU.1. This enhancer 
also mediates RUNX1 expression in T-ALL cells (237). However, upstream 
regulators of RUNX3 expression in T-ALL cells as well as in T-cells remain to be 
identified. Motif analysis in the regulatory regions of RUNX3 can uncover 
regulators of RUNX3 expression.   
RUNX proteins as therapeutic targets. 
 The results of genetic depletion of RUNX/CBFb complexes and treatment 
with the AI-10-104 inhibitor suggest that targeting RUNX proteins could be an 
effective treatment for T-ALL. The AI-10-104 compound was designed to 
interfere with CBFb binding to RUNX proteins, leading to inhibition of the 
transcriptional activities of the RUNX/CBFb complexes. Consistent with this, AI-
14-91, an analog of AI-10-104, was shown to reduce the binding of RUNX1 at its 
target sites and interfere with RUNX1-regulated genes in an in vitro 
hematopoietic progenitor cell differentiation system (366). AI-14-91 may also 
impede the role of RUNX1 in chromatin structure formation, which could be 
tested in future experiments.  
Due to the toxicity of AI-10-104 in mice (sedative effects), it was not 
possible to test its anti-leukemic activity in vivo. Instead, the analog compounds 
AI-14-91 and AI-12-126 are well-tolerated in mice (366). I tested the potency of 
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AI-12-126 in NOD-Scid IL2rg-/- (NSG) mice transplanted with a primary T-ALL 
patient sample and in FVB/N mice transplanted with Tal1/Lmo2 mouse T-ALL 
cells, but did not observe any inhibition of T-ALL growth in vivo (Appendix I). The 
relatively low activity of AI-12-126 compound (366) might not be able to target 
RUNX proteins in vivo. Therefore, testing the efficacy of AI-14-91 in T-ALLs in 
vitro and in vivo, which exhibits similar activity to AI-10-104 in fluorescence 
resonance energy transfer (FRET) assay (366), will be valuable to evaluate the 
benefit of targeting RUNX proteins in T-ALL inhibition.     
In my experiments, treatment of human T-ALL cell lines with AI-10-104 
reduced MYC expression, consistent with the notion that the inhibitor interferes 
with RUNX1 binding to the MYC enhancer locus. However, I did not detect 
significant reductions in MYB expression upon inhibitor treatment, in contrast to 
what was observed with genetic depletion of RUNX1. In addition, AI-10-104 
treatment downregulated NOTCH1 target genes including IL7R and DTX1, 
whereas genes that are regulated by TAL1 complex did not respond to AI-10-104 
treatment (data not shown). Based on these data, I hypothesize that CBFb is not 
necessary for RUNX1 to form the TAL1 transcriptional complex, while it binds as 
a heterodimer with RUNX1 to DNA regions that are also bound by NOTCH1. 
Other transcription factors that comprise the TAL1 autoregulatory complex can 
enhance the DNA binding capability of RUNX1, as a substitute for CBFb function. 
It has been suggested that ETS1 can form a complex with RUNX1 and increase 
RUNX1 DNA binding affinity without CBFb (412,413). ETS1 has been shown to 
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be a component of the TAL1 transcription complex in multiple hematopoietic cell 
types (373,414). In addition, the ETS binding motif was one of the top enriched 
sequences near TAL1 binding sites in T-ALL (93,237), indicating that a RUNX1 
ETS1 may be a component of the TAL1 complex and regulate TAL1 regulated 
genes in leukemic cells. Thus, AI-10-104, which inhibits RUNX1 activity by 
preventing CBFb binding may not affect RUNX1 regulation of TAL1 target genes, 
like MYB. To clearly elucidate the contribution of CBFb to the formation of the 
TAL1 complex and regulation of TAL1 complex-target genes, genetic analysis of 
CBFb in T-ALL will be necessary. Binding of CBFb at regulatory loci of the TAL1 
complex-target genes can be examined. In addition, expression of the TAL1 
complex-target genes can be tested in CBFb depleted T-ALL cells using shRNA 
or CRISPR/CAS9 system. Nevertheless, based on the prevalence of NOTCH1 
activation in T-ALL, interfering with NOTCH1 pathway by inhibiting CBFb  binding 
to RUNX1 could be a viable T-ALL therapy.       
Recently, the dosage-dependent function of RUNX proteins has been 
proposed that profound suppression of RUNX proteins result in cell cycle arrest 
and death in AML (415). Partial reduction of RUNX activity by expressing a loss-
of-function mutant of RUNX1 resulted in the expansion of myeloid progenitor 
cells and AML development, consistent with the tumor-suppressive role of 
RUNX1. On the other hand, RUNX depletion inhibited the growth of cord blood 
cells transduced with RUNX1-ETO or MLL-AF9 fusion genes indicating the pro-
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survival function of RUNX1. Moreover, double deletion of RUNX1 and CBFb, 
which further suppresses total RUNX activity, led to substantial reduction of cell 
growth (415). Similarly, the pro-survival role of wildtype RUNX1 has been 
demonstrated in AML expressing CBFb-SMMHC and in B-ALL expressing MLL 
fusion proteins. Decrease of wildtype RUNX1 in the Kasumi-1 cell line that 
harbors a t(8;21) translocation, creating RUNX1-ETO fusion gene, or in the 
inv(16) ME-1 cell line expressing CBFb-SMMHC fusion protein resulted in 
leukemic cell apoptosis (416). In addition, RUNX1 was shown to support the 
growth of MLL-AF4 leukemic cells as a direct target of the MLL-AF4 fusion 
protein and a component of MLL-AF4 complex (417). It is supported by the 
observation that RUNX1 mutations have not been identified in primary patient 
AML cells transformed by fusion genes (305,306,310) and that high expression 
levels of RUNX1 is associated with poor prognosis in MLL-rearranged leukemia 
(417). Therefore, targeting wildtype RUNX1 may be beneficial in treating other 
types of leukemia besides T-ALL.       
It should be noted that RUNX1 inhibition as an anti-leukemia strategy has 
risks as recurrent mutations of RUNX1 are associated with familial platelet 
disorder (FPD) which predisposes to AML. FPD patients harbor mutations that 
result in dominant-negative or loss-of-function in RUNX1 activity (418,419). 
Furthermore, the acquisition of additional somatic loss of function mutations in 
the wildtype RUNX1 allele is frequently associated with AML development 
(278,420,421). Induced pluripotent stem cells (iPSCs) from FPD/AML patients 
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harboring RUNX1 mutations exhibit megakaryopoiesis defects, supporting that 
RUNX1 suppression can result in platelet disorder (422–424). Therefore, long-
term inhibition of RUNX1 in T-ALL may increase the incidence of 
thrombocytopenia or AML development. Recently, de novo RUNX1 mutations 
were also reported in patients with thrombocytopenia (421,425). Thus, the 
intensity and duration of RUNX1 targeted therapy will need careful consideration 
to minimize adverse effects.    
Future directions 
I have investigated the role of RUNX1 in T-ALL leukemogenesis, 
especially focused on how RUNX1 controls oncogenic enhancer activity. Since I 
demonstrated that RUNX1 is involved in chromatin looping formation around the 
MYB gene, it would be interesting to explore the chromatin looping structures 
around the MYC gene using a 5C (Chromosome conformation capture carbon 
copy) assay. The distance between the promoter and enhancer (N-Me) of MYC 
is around 1.4 Mb, which is not suitable for 3C experiment. While 3C assay can 
examine interactions of a selected fragment with others within several hundred 
kb, 5C assay can investigate interactions between all digested fragments within a 
given region, which can be up to megabases (426). Getting the adequate 
suppression of RUNX1 expression in the doxycycline-inducible shRNA-RUNX1 
cell line was difficult when I performed the 3C experiment for MYB region. To 
overcome this difficulty, we could use Tal1/Lmo2/R26-CreERT2Runx1f/f mouse T-
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ALL model system, where the Runx1 deletion is easily achieved by 4-OHT 
treatment. Furthermore, since mouse T-ALL cell lines proliferate faster than 
human T-ALL cell lines, we should be able to find a time point that would be long 
enough to detect chromatin structure change without having significant effects on 
cell death. It was shown that the interaction between the promoter and MYC 
enhancer locus (N-Me) was not altered by short-term (6 hours) NOTCH1 
inhibition with g-secretase inhibitor (GSI) treatment, while it was disrupted in 
persister cells treated with GSI for a longer time (208). These results indicate that 
cells need a certain amount of time to undergo chromatin structure changes.  
Interestingly, the interaction between the promoter region and a super-
enhancer locus at 1.7 Mb downstream from the TSS of MYC, that is highly bound 
by BRD4 (bromodomain-containing protein 4), (BRD4 Dependent Myc Enhancer, 
BDME), was maintained in GSI-resistant persister cells although the NOTCH1 
expression was undetectable (207,208). In those cells, binding of BRD4, which is 
required for the survival of persister cells, was sustained or even increased at 
BDME while diminished at N-Me, suggesting that a chromatin modification 
protein BRD4, not NOTCH1 is responsible for the loop formation (208). In AML 
cells, reduced BRG1 altered the interaction of BDME with MYC promoter without 
changes in binding of transcription factors (352). Thus, it is possible that RUNX1 
does not determine the interaction between the MYC promoter and enhancer loci. 
In GSI-resistant persister cells, on the other hand, RUNX1 is one of the top-
ranked genes bound by BRD4 (207), suggesting upregulation and a role of 
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RUNX1 in GSI-resistant cells. Since RUNX1 binds to BDME, it is possible that 
RUNX1 regulates BRD4 binding to BDME as it does for TAL1 and NOTCH1 
binding to MYB and MYC enhancer, and contributes to the interaction between 
MYC promoter and BDME regions,  which can be tested by ChIP and 5C 
experiments (207). The results of these experiments raise the possibility that 
RUNX1 regulates chromatin structure associated with epigenetic alterations in 
GSI-resistant cells. By using a Hi-C (high-resolution chromosome conformation 
capture) technique, we can examine the genome-wide chromatin conformation 
changes in naïve and GSI-resistant leukemic cells and test the role of RUNX1 in 
these epigenetic changes by deleting RUNX1 in inducible CRISPR/CAS9 system. 
To examine a case that chromatin modification proteins but not RUNX1 mediate 
the chromatin structure changes, occupancy of chromatin modifiers at the 
interacting loci can be tested in the absence of RUNX1. Based on my preliminary 
ATAC-seq data (Appendix II), RUNX1 may control DNA accessibility to promoter 
regions of genes involved in chromatin organization and histone modification, 
suggesting that RUNX1 indirectly regulates chromatin conformation.  
I have studied the function of RUNX1 in T-ALL leukemogenesis in the 
context of TAL1 and NOTCH1 activation based on their shared target genes. 
Even though it appears that RUNX1 shares approximately 70% of target loci with 
TAL1 and NOTCH1, ChIP-seq and gene expression profile data revealed a 
subset of genes that are regulated by RUNX1 only (237,325). One of the 
intriguing pathways enriched with RUNX1-only-regulated genes is mTOR 
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signaling. The PI3K-AKT-mTOR pathway is upregulated in 70-85% of pediatric 
patients with T-ALL (209). In addition, activation of mTOR signaling has been 
implicated in the survival and proliferation of T-ALL LICs (427,428). RICTOR, a 
specific component of the mTORC2 complex is identified as a direct target gene 
of RUNX1. The mTORC2 complex was proposed to activate AKT through 
phosphorylation (429). Deletion of Rictor delayed NOTCH1-induced T-ALL 
development in vivo, suggesting a role for mTORC2 in T-ALL (430). Notably, 
NOTCH1 has been known to mediate mTOR signaling through the transcriptional 
repression of PTEN by HES1 (154) whereas expression of HES1 is not changed 
by RUNX1 depletion. Therefore, in future studies, it would be interesting to 
investigate whether RUNX1 inhibition ablates mTOR signaling in T-ALL 
development.  
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Figure 4.1. Proposed Model. This thesis research demonstrates that RUNX1 
functions as an oncogene in T-ALL cells by regulating the transcriptional activity 
of TAL1 or NOTCH1. RUNX1 regulates the expression of MYB and MYC, which 
are critical oncogenes of T-ALL, by controlling TAL1 and NOTCH1 binding and 
acetylation of histone 3 lysine 27 at the MYB and MYC enhancer regions. 
Inhibition of RUNX1/3 activity interferes with NOTCH1 and TAL1 binding to the 
enhancer loci and leads to closed chromosome configuration resulting in 
disruption of the oncogenic pathway and death of leukemic cells.   
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Appendix I 
Evaluation of the efficacy of RUNX/CBFb inhibitor AI-12-126 on T-ALL 
progression in vivo.  
 I have demonstrated that the RUNX/CBFb inhibitor AI-10-104 induces 
growth inhibition and apoptosis in human and mouse T-ALL leukemic cells in 
vitro (Chapter II).  These data suggest that targeting RUNX proteins can be a 
therapeutic option for patients with T-ALL. However, due to observed toxicity in 
mice, I was not able to test the efficacy of AI-10-104 inhibitor in vivo. An analog 
molecule, AI-12-126, was subsequently developed by Dr. Bushweller’s laboratory, 
which is well-tolerated in mice (366). Thus, I attempted to validate the therapeutic 
effects of RUNX proteins inhibition in vivo using the AI-12-126 inhibitor. 
 The efficacy of AI-12-126 was determined in mice transplanted with a 
primary human T-ALL sample or Tal1/Lmo2 mouse T-ALL cells. NOD-scid Il2rg-/- 
(NSG) mice were transplanted with the TALL-X-7 primary human T-ALL sample 
(1x106), which expresses TAL1, RUNX1, and mutated NOTCH1. When CD45+ 
human T-ALL blasts reached approximately 10% engraftment in the mouse 
peripheral blood, vehicle (Captisol) or AI-12-126 was administered at 100 mg/kg 
to mice by intraperitoneal (IP) injection daily for 2 weeks (Figure A.I.1A). 
Tal1/Lmo2 mouse T-ALL cells (1x105) were transplanted to syngeneic mice and 
vehicle or the same dose of AI-12-126 were administered for 3 weeks starting at 
the time of transplant (Figure A.I.2B). For the survival assay, mice were 
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monitored and euthanized when they became moribund. To assess the leukemic 
burden in vivo, mice were sacrificed after 2 (for NSG mice) or 3 weeks (for 
FVB/N syngeneic mice) of treatment. The spleen weights and total BM cellularity 
of AI-12-126 treated mice were similar to those of vehicle treated mice (Figure 
A.I.1B and 2B). In addition, AI-12-126 treatment did not prolong the survival of 
mice transplanted with leukemic cells (Figure A.I.2C), indicating that AI-12-126 
did not inhibit leukemic cell growth in vivo.  
 Pharmacokinetic analyses revealed that the half-life of AI-12-126 in the 
mouse peripheral blood was approximately 179 minutes a following IP injection, 
which seems to be reasonable (366). However, a FRET assay (366) and cell 
growth assay (Figure A.I.3) suggested that AI-12-126 has lower activity 
compared to AI-10-104 compound. These data suggest that AI-12-126 might not 
effectively target RUNX/CBFb proteins in vivo, which should be examined using 
RUNX1/3-target gene expression profiling in leukemic cells of AI-12-126 treated 
mice. In addition, the development of other compounds that target RUNX 
proteins more efficiently without in vivo toxicity is required in order to evaluate 
RUNX1 as a therapeutic target for T-ALL.  
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Figure A.I.1. AI-12-126 treatment does not suppress leukemia progression 
in mice transplanted with primary patient T-ALL sample. (A) Experimental 
scheme to determine the efficacy of AI-12-126 compound on leukemia 
progression in vivo. NSG mice were intravenously injected with 1x106 primary 
human T-ALL blasts (TALL-X-7) and bled weekly to determine the percentage of 
circulating human CD45+ cells in the mouse peripheral blood. When human 
leukemic blasts reached approximately 10% engraftment in the peripheral blood, 
vehicle (Captisol, n=4) or AI-12-126 (100 mg/kg, n=5) were administered daily to 
mice by intraperitoneal injection for 2 weeks. (B) The in vivo response of the 
primary human T-ALL sample to AI-12-126 treatment was assessed by spleen 
weight and total BM cellularity.  
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Figure A.I.2. Treatment of AI-12-126 does not inhibit leukemic growth in 
vivo. (A) Experimental strategy to determine the efficacy of AI-12-126 on 
leukemic cell growth in vivo. Tal1/Lmo2 mouse T-ALL cells (1x105) were 
transplanted into syngeneic recipients and vehicle or AI-12-126 was administered 
at 100 mg/kg daily for 3 weeks. Administration of vehicle or AI-12-126 started at 
the time of transplant. (B) To examine leukemic burden, mice were sacrificed 
following 3 weeks of treatment and spleen weight and total BM cellularity were 
determined (C). For the survival assay, mice were monitored for disease and 
sacrificed when moribund. Kaplan-Meier survival curve is shown. 
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Figure A.I.3 AI-12-126 treatment inhibits the growth of human T-ALL cell 
lines. Jurkat, KOPTK1, PRMI8402, and MOLT4 human T-ALL cell lines were 
treated with AI-4-88, AI-10-104, or AI-12-126 for 3 days and the growth of 
leukemic cells were determined using an MTS cell viability assay reagent. IC50 
was calculated using Prism7 software.    
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Appendix II 
RUNX1 regulates DNA accessibility in mouse T-ALL cells 
 RUNX1, as a transcription factor, binds to DNA to activate or repress its 
target genes and is also suggested to play a role in chromatin structure formation 
(43,394). RUNX1 interacts with BRG1, a component of the SWI/SNF chromatin 
remodeling complex (43). During definitive hematopoiesis, RUNX1 has been 
shown to unfold chromatin and increase DNaseI accessibility around the Pu.1 
gene leading to expression of Pu.1  (431). I have demonstrated that Runx1 
deletion in mouse T-ALL cells increases histone 3 recruitment to the Myb and 
Myc enhancers (Figure 3.4, 3.5). Therefore, I investigated genome-wide changes 
in chromatin accessibility upon Runx1 deletion in mouse T-ALL cells using an 
ATAC-seq experiment (Assay for Transposase-Accessible Chromatin using 
Sequencing).  
 To delete Runx1, I treated Tal1/Lmo2/Rosa26-CreERT2Runx1f/f mouse 
T-ALL cells with 4-OHT for 24 hours and collected cells after an additional 24 
hours. I isolated nuclei to reduce mitochondrial DNA contamination, which 
accounts for 40% of the total DNA quantity in mouse T-ALL cells, and generated 
the ATAC-seq library as described (384) (Chapter III methods and materials). 
Fragments from the library were sequenced using paired-end reads on the 
Illumina HiSeq 2000 instrument and the resulting sequence reads (approximately 
200 million reads) were aligned to the mouse genome (mm10) using the Bowtie2 
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algorithm with help of Dr. Jun Yu and Dr. Julie Zhu at the University of 
Massachusetts Medical School. To identify nucleosome free-DNA regions, we 
focused on ATAC-seq signals aligned with reads smaller than 100 base pairs 
(432).   
 ATAC-seq analysis revealed that Runx1 deletion induces genome-wide 
changes in chromatin accessibility (Figure A.II.1). A large number of regions 
became accessible (open chromatin regions) upon Runx1 deletion. In the 
presence of RUNX1, 8081 loci were accessible while 11776 loci became 
accessible upon RUNX1 deletion. Since chromatin accessibility corresponds to 
transcriptional activity (433,434), we annotated genes associated with open or 
closed chromatin upon Runx1 deletion to identify RUNX1-regulated genes. Since 
we do not have information about genome-wide enhancer loci in mouse T-ALL 
cells, we examined the ATAC-seq signals around promoter regions (5 kb up and 
downstream from the TSS, false discovery rate (FDR) <0.05, absolute log2-fold-
change<2). Consistent with the result that Runx1 deletion induced cell death, the 
accessibility to promoters of several pro-apoptosis genes such as Bad, Bag6, 
Bcl7a, and Bcl2l11 were increased upon Runx1 deletion. ATAC-seq signals at 
the promoter of Cdkn1a, which was upregulated upon Runx1 deletion (Chapter III, 
Figure 3.1A) and negatively regulates cell cycle progression (435), was also 
increased in Runx1 deleted cells. In addition, the promoter of Cdkn2c, which has 
been suggested as a tumor suppressor as a member of the INK4 family (436), 
was open upon Runx1 deletion. These results support the idea that Runx1 
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deletion represses the growth of T-ALL cells by regulating involved gene 
expression. Examination of expression change of these genes should be 
followed to confirm RUNX1 regulation of these genes.    
Interestingly, 2082 gene promoters became accessible whereas only 120 
promoter regions were closed upon Runx1 deletion, which precluded functional 
annotation analyses. Thus, we performed pathway and gene ontology (GO) 
enrichment analyses with open promoter regions upon Runx1-deletion. These 
analyses revealed that genes involved in RNA biogenesis, including RNA 
transport, ribonucleoprotein complex biogenesis, and splicing, were associated 
with open chromatin structures in Runx1-deleted T-ALL cells. In addition, 
promoter loci of genes that mediate histone modification and regulation of 
chromosome organization were accessible in Runx1 deleted cells, suggesting 
that RUNX1 may repress the expression of genes involved in RNA biogenesis 
and chromatin remodeling. Genes belonging to each group are listed in Table 
A.II.1.  
RUNX proteins are known to regulate ribosome biogenesis, which 
involves cell growth, cell cycle, and differentiation (437–439). The total amount of 
ribosome protein mRNAs and rRNAs in Runx1-deficient hematopoietic stem cells 
(HSCs) is reduced compared to wild-type HSCs, which is not evident in Runx1-
deleted multipotent progenitor cells (MPPs) (437). RUNX1 and RUNX2 were 
shown to localize at nucleolar organizing regions in mitotic chromosomes where 
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rRNA genes reside. RUNX2 depletion, on the other hand, enhanced the 
synthesis of rRNAs in the SAOS-2 human osteosarcoma cell line (439). 
Therefore, RUNX1 appears to regulate rRNA expression and ribosome 
biogenesis in a cell-type dependent manner. The increased accessibility to 
promoter regions in Runx1-deleted cells suggests that RUNX1 represses 
ribosome biogenesis in T-ALL, which needs to be validated by expression 
change of the rRNA genes upon Runx1 deletion. To examine the RUNX1 
regulation of rRNA genes, which would change the total transcript amount, 
normalization of the gene expression should be performed based on the amount 
of external RNA controls (spike-in controls) added in proportion to the cell 
number. The enriched RUNX1 binding at rRNA genes can be tested using ChIP-
seq to confirm direct RUNX1 regulation of those genes. However, the decreased 
cell growth in RUNX1 depleted cells (Chapter II) indicates that ribosome 
biogenesis would be decreased in Runx1 deleted cells, which contradicts the 
ATAC-seq data.      
Promoters of genes encoding histone modification enzymes, including 
histone methyltransferases (Kmt2a [histone-lysine N-methyltransferase 2A], 
Setd1a [histone-lysine N-methyltransferase SET domain 1A], Ehmt2 
[euchromatic histone-lysine N-methyltransferase 2]), and histone 
demethyltransferase (Jmjd6 [arginine demethylase jumonji domain containing 6], 
Kdm6b [lysine demethylase 6B]), and histone acetyltransferase (EP300, Kat14 
[lysine acetyltransferase 14], and Msl1 [male specific lethal 1 homolog]) became 
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accessible upon Runx1 deletion, suggesting that RUNX1 may repress the 
expression of these genes. RUNX1 has been demonstrated to bind and 
cooperate with histone modification or remodeling cofactors such as EP300 and 
BGR1 (39,43). Therefore, it would be interesting to investigate whether RUNX1 
regulates chromatin conformation by controlling the expression of these genes.  
Histone modification changes resulting from gene expression alteration can be 
evaluated using ChIP-seq for methylated or acetylated histones. Since both 
histone methyltransferase and demethyltransferase were suggested to be 
activated, the net change in methylation is unclear. 
More number of loci were accessible in Runx1-deleted cells than in 
Runx1-wildtype cell (11776 versus 8081 loci), suggesting that Runx1 deletion 
results in open chromatin structure overall. It is an unexpected result because 
that an accessible chromatin structure is associated with active gene expression 
and that a similar number of genes were upregulated or downregulated in a 
RUNX1-depleted Jurkat human T-ALL cell line (237). Furthermore, in contrast to 
the gene expression profiles that were downregulated by Runx1 deletion 
(Chapter III, Figure 3.1), increased accessibility at promoters of Gata3, Cdk6, 
and Igf1r upon Runx1 deletion was identified by ATAC-seq, suggesting active 
transcription of these genes. In addition, the accessibility to the Myb and Myc 
enhancer regions was increased in Runx1-deleted cells (Figure A.II.2), which is 
not consistent with increased histone 3 recruitment to these enhancers (Chapter 
III. Figure 3.5, 3.5). These inconsistencies suggest that the experiment may not 
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have been performed optimally. During the additional nuclei isolation process for 
reducing mitochondrial DNA contamination, nuclei could be damaged or fewer 
number of nuclei were collected, which would result in increased accessibility of 
transposase to DNA. On the other hand, cells used for library generation might 
have already initiated apoptosis and lost chromatin integrity. Even though I did 
not detect a significant amount of dead cells at the time of cell collection and also 
performed live-cell purification using ficoll-plaque gradient centrifugation, it is 
possible that cells undergoing apoptosis were still retained in the population. In 
these cases, DNA could be over-tagmented by transposase, resulting in non-
specific ATAC-seq signals. Thus, careful validation of the ATAC-seq results by 
examination of gene expression alteration or polymerase II recruitment is 
required. Furthermore, since ChIP-seq for RUNX1 showed that more than 60% 
of RUNX1 binding loci are located at enhancer regions in human T-ALL cells 
(324), evaluation of chromatin accessibility changes at the enhancer loci upon 
Runx1 deletion may be more informative. To map enhancer regions in the mouse 
T-ALL genome, ChIP-seq experiments for H3K27ac or H3K4me1, which marks 
active enhancer regions (440,441), should be performed.  
A study of DNase I hypersensitivity combined with an expression profile 
showed that, even though there is a trend, a correlation between the degree of 
DNAase I hypersensitivity and the expression level is not strong (Pearson’s 
R=0.09) (433). Therefore, in addition to ATAC-seq, RNA-seq and ChIP-seq for 
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histone marks of Runx1 deleted mouse T-ALL cells will be required to reveal 
correlations between gene expression and chromatin accessibility. 
	
	
 
 
 
Figure A.II.1. Signals of ATAC-seq in Runx1 deleted mouse T-ALL cells and 
over-represented pathways. (A) Scatter plot of ATAC-seq in Runx1 deleted 
mouse T-ALL cells compared to untreated cells. (B-D) KEGG pathway, GO 
biological process, and GO molecular function analyses with promoter regions 
which are open upon Runx1 deletion (Cutoff: FDR<0.05, |log2FC|>2 for promoter 
regions). 
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Figure A.II.2. The accessibility to the Myb and Myc enhancer regions is 
increased in Runx1-deleted cells. (A,B) Genome browser tracks show ATAC-
seq signals around Myb -92 kb (A) and Myc +1.27 Mb (B) regions. The signals 
are increased in Runx1-deleted cells compared to Runx1-wildtype cells.  
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Appendix III 
 
Repression of mTORC1 activity sensitizes T-ALL cells to ABT-263 
treatment 
Data from the following section were submitted as a manuscript not yet in print: 
Anahita Dastur#, AHyun Choi#, Carlotta Costa, Xunqin Yin, August Williams, Justine 
Roderick, Joseph McClanaghan, Neha U. Patel, Jessica Boisvert, Ultan McDermott, 
Mathew J. Garnett, Jorge Alemenara, Steven Grant, Kathryn Rizzo, Jeffrey A. Engelman, 
Michelle Kelliher, Anthony C. Faber, and Cyril H. Benes. NOTCH1 represses MCL-1 
levels in T-ALL, making them susceptible to ABT-263. (2018) Cancer Research, Under 
review.		
# Denotes co-first author 
 
The manuscript has been edited for this thesis to show the results performed by AHyun 
Choi.  
  
 Activating mutations of NOTCH1 have been identified in more than 50% of 
T-ALL patient cases (151). Accordingly, therapies targeting NOTCH1 have been 
evaluated in clinical trials, but they have not been successful; patients treated 
with GSI suffered from continued disease progression and on-target toxicities in 
other tissues, such as the gastrointestinal tract (229). In an effort to identify 
alternative therapeutic strategies for T-ALL, Benes and colleagues previously 
performed a high-throughput drug screen across hundreds of human cancer cell 
lines (442). This screen uncovered that both GSI-sensitive and resistant T-ALL 
cell lines were highly sensitive to the BH3-mimetic ABT-263 (Navitoclax) 
compound, an inhibitor of anti-apoptotic proteins BCL-2, BCL-xL, and BCL-w 
(442,443). Apoptosis process is regulated by interactions among BCL-2 family 
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proteins that either promote or inhibit apoptosis. Anti-apoptotic proteins, such as 
BCL-2, BCL-xL, BCL-w, and MCL-1, bind and sequester pro-apoptotic proteins, 
including BAK, BAX, BIM, and BAD, to prevent cells from death, following 
mitochondrial outer membrane permeabilization (MOMP) (444). ABT-263 inhibits 
BCL-2, BC-xL and BCL-w by binding to them that results in release and 
activation of pro-apoptotic proteins (443,444).      
In this study, treatment of human T-ALL cell lines with ABT-263 resulted in 
growth inhibition and apoptosis of leukemic cells. Consistent with previous 
studies, we found that low expression levels of MCL-1 determines the high-
sensitivity of T-ALL cell lines to ABT-263 (442,445). MCL-1 is not bound by ABT-
263 and MCL-1 sequesters free BIM released from BCL-2/BIM or BCL-xL/BIM 
complexes upon ABT-263 treatment (446). In addition, among the human T-ALL 
cell lines, GSI-sensitive T-ALL lines, such as KOPTK1, DND-41, and ALL-SIL 
(which express relatively lower levels of MCL-1 compared to GSI-resistant lines), 
were more sensitive to ABT-263 treatment. It has been known that mTORC1 
controls the translation of MCL-1 in a cap-dependent manner (447–449) and, in 
agreement with this, mTORC1 inhibition by treatment of an mTORC1/2 inhibitor, 
AZD8055, decreased MCL-1 protein levels. Furthermore, combination treatment 
of AZD8055 and ABT-263 significantly induced apoptosis of T-ALL cell lines and 
primary patient samples in vitro (data not shown).  
 In order to validate the therapeutic effects of the combination treatment, 
we administrated ABT-263 and AZD8055 to NOD-scid Il2rg-/- (NSG) mice 
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transplanted with primary human T-ALL blasts. A GSI-sensitive (TALL-X-7) and a 
GSI-resistant (TALL-X-2) primary patient sample were engrafted into mice and 
administered when 55-65 % of leukemic blasts were detected in the blood 
(Figure A.III.1). When both ABT-263 and AZD805 compounds were administered 
to mice transplanted with GSI-resistant patient sample, mice survived 
significantly longer than those treated with either ABT-263 or AZD8055 alone 
(Figure A.III.2A). In addition, the combination treatment of ABT-263 and 
AZD8055 more effectively inhibited the growth of human leukemic cells in mice 
(Figure A.III.3). However, in mice transplanted with the GSI-sensitive primary 
patient sample, the efficacy of combination treatment was similar to that of ABT-
263 treatment alone (Figure A.III.2B and 4). These data are consistent with in 
vitro results that combination treatment is more effective in GSI-resistant T-ALL 
cells (data not shown).  
 These results suggest that ABT-263 could be an effective therapeutic 
compound for patients with T-ALL. In addition, treatment with mTOR inhibitor 
AZD8055 augmented the efficacy of ABT-263 in GSI-resistant T-ALL cells. Given 
that activation of the mTOR pathway is prevalent in T-ALL (154,209,210), the 
combination of ABT-263 and AZD8055 could be a promising therapy for T-ALL 
patients. Interestingly, we did not detect a difference in expression levels of 
MCL-1 across GSI-sensitive and resistant primary patient samples, which is not 
consistent with T-ALL cell lines (Data not shown, Figure A.III.5). This indicates 
that something other than the level of MCL-1 expression can influence the 
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sensitivity of ABT-263. We also observed that growth of one of primary relapse 
T-ALL samples (TALL-X-15) was not inhibited by ABT-263 treatment at all (data 
now shown). Therefore, further studies designed to understand the underlying 
mechanism of ABT-263 efficacy are required.   
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Figure A.III.1. Experimental strategy of used to determine the efficacy of 
combination treatment of AZD8055 and ATB-263 on leukemia progression 
in vivo. NSG mice were intravenously injected with 1 x 106 primary human T-ALL 
blasts and bled weekly to determine the percentage of circulating human CD45+ 
cells in the peripheral blood. Once the leukemic burden reached 55% (TALL-X-7) 
or 65% (TALL-X-2) human leukemic blasts in the peripheral blood, mice were 
randomized to one of four treatment groups. Vehicle, AZD8055 (16mg/Kg, diluted 
in Captisol), ABT-263 (80mg/Kg, diluted in 60% Phosal 50 PG, 30% PEG 400 
and 10% EtOH) or both AZD8055 and ABT-263 were administered to mice by 
oral gavage for 2 or 3 weeks using a 6-day on, 1-day off regimen. For the 
survival assay, mice were administrated with compounds for 3 weeks, monitored 
daily, and sacrificed when moribund. To assess leukemic burden, animals were 
sacrificed following 2-weeks of treatment and the percentage of human CD45+ 
leukemic cells in mouse spleen, bone marrow, and peripheral blood were 
determined by flow cytometry. All mouse procedures used in this study were 
approved by the University of Massachusetts Medical School Institutional Animal 
Care and Use Committee. 
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Figure A.III.2. Treatment of AZD8055 and ABT-263 prolong survival of mice 
transplanted with primary T-ALL patient samples. Kaplan-Meier survival 
curves are shown for TALL-X-2 (B) and TALL-X-7 (C) samples. The difference in 
overall survival between the treatment groups was assessed by log-rank test 
using GraphPad Prism software, V7.0 (*p<0.05, *** p<0.001, **** p<0.0001).  
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Figure A.III.3. Combination treatment of AZD8055 and ABT-263 inhibits 
leukemic burden in vivo. In vivo response of the TALL-X-2 primary T-ALL 
sample to ABT-263, AZD8055, or combination of ABT-263 and AZD8055 
treatment was determined by counting total number or percentage of human 
CD45+ leukemic blast in mouse peripheral blood (A), spleen (B), and bone 
marrow (C). Mice were sacrificed at 2-weeks post-treatment. 
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Figure A.III.4. The in vivo growth of TALL-X-7 primary T-ALL patient sample 
is suppressed by treatment with ABT-263. The total number and percentage 
of human CD45+ leukemic blasts in mouse peripheral blood, bone marrow, and 
spleen were counted to determine the in vivo response of TALL-X-7 primary T-
ALL patient sample to 2-week administration of ABT-263, AZD8055, and 
combination of ABT-263 and AZD8055. 
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Figure A.III.5. The expression of intracellular NOTCH1 and MCL-1 in primary 
T-ALL patient samples. Protein lysates from primary T-ALL patient samples 
were separated on an SDS-PAGE gel and intracellular NOTCH1 and MCL-1 
protein levels were determined by immunoblotting. b-Actin was used as a loading 
control.  
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Appendix IV 
Attempts to identify a compound that selectively kills ETP-ALL cells 
 Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a 
subtype of T-ALL that accounts for approximately 15% of pediatric and 10-30% 
of adult patients with T-ALL (130,450–453). It is distinguished from typical T-ALL 
subtypes by a distinct immunophenotype of CD1a-, CD8-, and CD5weak with 
aberrant expression of hematopoietic stem or myeloid cell markers including 
CD13, CD33, CD34, and CD117 (130). Genomic analyses have demonstrated 
that ETP-ALL is associated with increased genomic instability and harbors 
diverse mutations (131,130). Activating mutations of cytokine receptors and RAS 
signaling, such as FLT3, IGFR1, JAK1/3, KRAS, and NRAS, and inactivating 
mutations in hematopoietic development pathways and histone-modification has 
been frequently identified in ETP-ALL samples (131). Patients with ETP-ALL 
have an especially high-risk of treatment failure and relapse; the overall 
incidence of induction failure and relapse is over 50% in ETP-ALL patients 
(130,453,454). Therefore, there is an urgent need for development of alternative 
targeted therapies for this chemotherapy-refractory subtype of T-ALL.      
 To identify pharmacologically effective compounds to inhibit ETP-ALL 
survival, we performed small molecule screening using the Loucy cell line as a 
human ETP-ALL model. In collaboration with Dr. Sangram Parelkar and Dr. Paul 
Thompson at Small Molecule Screening Facility, University of Medical School 
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Massachusetts. The primary screen identified 42 compounds cytotoxic to Loucy 
cells. We selected 19 compounds that target pathways disrupted in cancer, 
including protein kinase C (PKC) and the NF-kB pathway, and tested their 
efficacy in Loucy cells in comparison to the Jurkat cell line, a typical T-ALL cell 
line (Table A IV.1). Six out of 19 compounds inhibited the proliferation of Loucy 
cells at low concentrations but were not deleterious to Jurkat cells (Figure A IV.1). 
These compounds included inhibitors of PKC, protein phosphatase 2A (PP2A), 
CDC25A phosphatase, or Vitamin A acid analog (Table A IV.2).  
PKC is a family of serine/threonine protein kinases that functions in cell 
proliferation, survival, and differentiation through mediation of signal transduction 
(455–457). PKC has been implicated in the tumorigenesis of several types of 
cancer including prostate, breast, lung cancer, and chronic lymphocytic leukemia 
(455,456,458–460). PP2A is also known to mediate PKC signaling (461). Thus, 
we further validated the screening results by treating Loucy and Jurkat cells with 
various concentration of Rottlerin (an PKCd and q inhibitor) and Cantharidin (an 
PP2A inhibitor). We also tested the efficacy of Retinoic acid p-hydroxyanilide (a 
Vitamin A acid analog) in the suppression of ETP-ALL cell growth since all-trans 
retinoic acid (ATRA) therapy has improved the outcome of acute promyelocytic 
leukemia (APL) (462). We observed that only Rottlerin inhibited the growth of 
Loucy cells selectively at a low concentration (Figure A.IV.2A). It also effectively 
repressed survival of primary ETP-ALL patient samples, though primary typical 
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T-ALL patient cells were equivalently sensitive to Rottlerin treatment (Figure 
A.IV.3B). 
 Targeting PKC signaling in ETP-ALL is especially intriguing based on the 
fact that several PKC isozymes are involved in RAS-mediated tumorigenesis 
(458,463–466). To date, 10 isozymes of PKC have been identified, which are 
sub-grouped into conventional (a, bI, bII, and g), novel (d, e, h, and q), and 
atypical (z, l/i) groups based on their structural similarity and co-factor 
requirements (455,456). PKCd and i have been shown to be required for K-RAS 
mediated lung cancer (458,463,464). PKCe isozyme activates RAF, a 
downstream kinase of RAS pathway (465,466). Thus, inhibiting certain PKC 
isozymes might suppress the activated RAS pathway in ETP-ALL.   
 However, targeting the PKC pathway to inhibit tumor progression does not 
appear to be straightforward. First, certain tissues express several PKC 
isozymes; some of these are functionally redundant and others interact to 
promote or antagonize each other’s activity (455,467,468). T-lymphocytes are 
known to express 8 PKC isozymes: a, b, d, e, h, q, z, and i, and PKCa and PKCb 
regulate IL-2 expression cooperatively (467,469). In addition, some PKC 
isozymes such as PKCa and d have been shown to function as tumor 
suppressors, depending on cellular context (456). A study with K-RAS-dependent 
lung cancer showed that PKCa suppresses tumor initiation and progression 
through p38 MAPK/TGFb signaling (470). Several studies implicate PKCd as a 
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pro-apoptotic and anti-proliferative kinase (471,472). Common mutations found in 
PKC isozymes resulting in reduced or abolished PKC activity also support tumor 
suppressing roles of PKC (473). Lastly, PKC-mediated K-RAS phosphorylation at 
Serine-181 reduced K-RAS activity, suggesting that inhibiting PKC might 
enhance K-RAS mediated transformation (474). Thus, further understanding 
about the roles of each PKC isozyme in various tissues is needed. In addition, 
developing molecules targeting specific PKC isozymes that function in ETP-ALL 
will be required.     
	 
152 
Table A IV.1. The list of compounds selected for the secondary screening. 
 
  
LOPAC ID Name Description
1839 rac-2-Ethoxy-3-octadecanamido-1-propylphosphocholine Protein kinase C (PKC) inhibitor
1982 Retinoic acid p-hydroxyanilide
Vitamin A acid analog with antiproliferative 
activity in cultured human breast cancer 
cells
1908 rac-2-Ethoxy-3-hexadecanamido-1-
propylphosphocholine
Protein kinase C (PKC) inhibitor
1598 Chelerythrine chloride PKC inhibitor; affects translocation of PKC 
from cytosol to plasma membrane
1787 ET-18-OCH3 Phosphoinositide-specific Phospholipase C (PI-PLC) inhibitor
1648 CGP-74514A hydrochloride Cdk1 inhibitor
1605 Cantharidin Protein phosphatase 2A inhibitor
1675 Cantharidic Acid Protein phosphatase 1 (PP1) and 2A 
(PP2A) inhibitor
2098 PM-20 Novel Cdc25A phosphatase inhibitor.
1674 Calcimycin
Ca2+ ionophore used to potentiate 
responses to NMDA, but not quisqualate 
glutamate receptors
2570 Terfenadine Non-sedating H1 histamine receptor 
antagonist
1540 Bay 11-7085 Inhibits cytokine induced IkB (Inhibitor of 
NFkB) phosphorylation
2409 Rottlerin PKC and CaM kinase III inhibitor
2473 DL-Stearoylcarnitine chloride Protein kinase C (PKC) inhibitor
1392 5-azacytidine DNA methyltransferase inhibitor
2281 TPCA-1
Potent and selective inhibitor of human IkB 
kinase-2 (IKK-2) used to study 
inflammation in animal models.
2302 Parthenolide
Inhibits serotonin release from platelets; 
inhibits production of leukotriene B4 and 
thromboxane B2
2111 Mevastatin
Antibiotic; inhibits post-translational 
prenylation of proteins such as Ras and 
geranylgeranylation of Rho
1862 Picropodophyllotoxin Insulin-like growth factor-I (IGF-I) receptor 
kinase inhibitor.
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Figure A.IV.1. Secondary screening identifies compounds that are 
selectively effective against the Loucy ETP-ALL cell line. Loucy and Jurkat 
cells were treated with compounds selected from primary screening for 3 days 
and the viability was measured using Celltiter-Blue cell viability assay reagent 
(Promega). Dr. Parelkar at the Small Molecule Screening Facility conducted 
experiments and I analyzed data using Prism7 Software.  
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Table A.IV.2. The list of 6 compounds identified in the secondary screening  
 
 
 
  
LOUCY Jurkat
1839 rac-2-Ethoxy-3-octadecanamido-1-propylphosphocholine 163702-18-9 PKC inhibitor 1.641 18.41
1982 Retinoic acid p-hydroxyanilide 65646-68-6 Vitamin A acid analog 13.58 ~ 21.28
1908 rac-2-Ethoxy-3-hexadecanamido-1-propylphosphocholine 112989-01-2 PKC inhibitor 1.138 15.32
1605 Cantharidin 56-25-7 PP2A inhibitor 3.268 ~ 41.54
2098 PM-20 863886-38-8  
Cdc25 
phosphatase 
inhibitor
N/D N/D
2473 DL-Stearoylcarnitine chloride 18822-91-8  PKC inhibitor 10.98 35.93
IC50 (µM)LOPAC ID Name Cas No. Description
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Figure A.IV.2. The sensitivity of compounds in ETP-ALL cell lines and 
primary patient samples. (A) Loucy and Jurkat cells were treated with a PKCd 
inhibitor Rottlerin (Santa Cruz Biotechnology), a Vitamin A acid analog Retinoic 
acid p-hydroxyanilide (Santa Cruz Biotechnology), and a PP2A inhibitor 
Cantharidin (Cayman) for 3 days. Jurkat and Loucy cells were plated with 104 
and 5x104 cells per well, respectively, in 96-well plates before treatment with the 
compounds. Cell viability was measured using Celltiter-Blue cell viability assay 
reagent, following the manufacturer’s instructions. Data presented are from 4 
biological replicates. (B) Primary typical T-ALL and ETP-ALL patient samples 
plated in 96-well plates at 105 cells per well density were treated with Rottlerin for 
3 days. Data are shown as mean of 2 to 4 biological replicates. Cell viability was 
determined using CelltiterGlo cell vitality assay reagent.  
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Appendix V 
 
 
Identification of tumor suppressor(s) in chromosome 6q deleted region that 
cooperate with TAL1 to cause T-ALL   
 
Among the cytogenetic abnormalities identified in T-ALL,  broad deletions 
of chromosome 6q have been observed in 10-30% of T-ALL and are associated 
with poor early treatment response (475–478). Downregulation of genes in these 
regions such CASP8AP2 (478), GRIK2 (479), and EPHA7 (480) have been 
observed in T-ALL and are proposed to be tumor suppressors. However, tumor 
suppressor(s) function has yet to be demonstrated.  
Recently, Mullighan’s group at St. Jude Children’s Research Hospital 
performed an integrated analysis that combined sequence mutations, DNA copy-
number alteration, and structural variant/rearrangement analysis of 264 pediatric 
T-ALL patient samples. They demonstrated that broad deletions with variant 
sizes on chromosome 6q14-q23 were present in 19.3% of cases, which were 
enriched in cases with TAL1, TLX1, LMO2, and NKX2-1 deregulation (150). The 
deleted regions were further refined using a computational approach called GRIN 
(genomic random interval model) into a 79.5 Mb to 97.1 Mb segment on 
chromosome 6, which was again highly associated with subgroups of LMO1/2 
rearrangement (30%), TAL1 (29%), TLX3 (23%). Furthermore, using RNA-seq 
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and copy number loss data, 38 genes were identified as the most commonly 
affected genes in the deleted region of 6q14.1 to q16.1 (150).  
Given that loss of gene(s) in this region appears to collaborate with 
LMO1/2 or TAL1 in T-ALL pathogenesis, we plan to test the transforming function 
of the candidate genes in our Tal1 or Tal1/Lmo2 T-ALL mouse model. Using the 
USCS genome browser, I identified mouse chromosome 4qA3-qA5 and mouse 
chromosome 9qE3-qE3.1 as the orthologous regions to human chromosome 
6q14.1-16.1 (Figure A.V.1). Thirty-two of 38 candidate genes identified in human 
T-ALL samples are conserved in the mouse genome. To identify genes involved 
in T-ALL development, shRNA library will be constructed consisting of multiple 
shRNAs to each of the conserved genes. Lentiviral stocks will be prepared and 
used to infect Tal1 or Tal1/Lmo2 T-ALL cells. Following puromycin selection, the 
growth of virus-infected cells will be examined in vitro or in transplanted 
syngeneic mice.  DNA from Cells that outcompete control-shRNA infected cells 
for growth will be collected and sequenced to identified silenced genes.  
We expect that suppression of the putative tumor suppressors will 
stimulate leukemic growth/survival in vivo and accelerate leukemogenesis in vivo. 
Since most of the deleted regions are broad containing more than one gene, 
multiple genes in the deleted regions appear to collaborate simultaneously in T-
ALL pathogenesis.   
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Figure A.V.1. The orthologous mouse genomic loci of human chromosome 
6q deleted regions. The most commonly deleted regions of chromosome 6q in 
human T-ALL are conserved in the mouse genome at chromosome 4q and 
chromosome 9q. The UCSC genome browser (genome.ucsc.edu) was used to 
determine the conserved regions in the mouse genome.     
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List of primers  
 
 
Table A.1 Primers for ChIP-qPCR 
 
 
 
 
Table A.2. Primers for ATAC-qPCR 
 
 
 
 
 
Supplementary Table 6. Primers for ChIP-qPCR
Target locus Direction Primer sequence (5' to 3')
ChIP-mNMe For AACCCTGAACCTGGTGATTG
Rev AGTGCTGGTGCCAAGAACTC
ChIP-mNMe H For CCCAACGTATTCCTCAACTGC
Rev AATGAAGTCACCTGCCCACT
ChIP-mMyb+15 For CTGTGTCTGGGGAAGGGGGT
Rev TCTTGCCTCCAACAGCATCT
ChIP-mMyb-92 For TGGTTTCCAGGGACCGTTAG
Rev GCAAACCACAGAGACTTGCA
ChIP-mMyb-92 H For TGGATCCACTGAGCAGAACA
Rev TGGCTTCCCTACTGAGCTGT
N.control  For AACCTCACACACAACAAGCTG
(Gene desert) Rev TGTGATAGGGAGAATGCTTGC
ChIP-mHes1pro For GACCTTGTGCCTAGCGGCCA
Rev AGACAGGGGATTCCGCTGTT
Supplementary Table 7. Primers for ATAC-qPCR
Target Locus Direction Primer sequence (5' to 3')
mNMe For AGAGGAGTTCTTGGCACCAG
Rev TTAGGCAGACTGCAGGGAAC
Gene Desert 1 For AACCTCACACACAACAAGCTG
Rev TGTGATAGGGAGAATGCTTGC
Gene Desert 2 For GCTACAAAAGAGTGAGGTCGT
Rev TTCCTACCCAGAAGTGTGCC
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